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ABSTRACT 
 
Alterations in Cystic Fibrosis Transmembrane conductance 
Regulator (CFTR) gene cause Cystic Fibrosis (CF), a disease 
whose complications lead to death due to respiratory failure. 
CFTR produces a primary transcript of 6132 bases, with a 
complex transcriptional regulation that depends on the entire 
locus of the gene. The correlation between genotype and 
phenotype in this pathology is still difficult to understand. 
We evaluated the possible mechanisms involved in the 
intragenic modulation of CFTR expression in CF and CF-like 
populations, already extensively characterized at the mutational 
level. Our study is based on three experimental approaches, 
applied to the CFTR gene of these populations: analysis of 
intragenic haplotypes; analysis of variant tracts (TG)mTn and 
effects on mRNA splicing; analysis of 3'-UTR for potential 
miRNAs recognition sites. We performed the structural 
analysis on DNA (by primer extension and Sanger sequencing) 
and the functional analysis on RNA (by reverse transcriptase 
PCR, densitometric analysis and Real-time PCR). 
Among the haplotypes characterized, one showed a 
significantly higher frequency in the populations of interest 
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(CF and CF-like) compared to control populations (general 
population and normospermic men), with a trend that varies 
according to the severity of the phenotypic manifestations. It 
has been highlighted that no anomalous splicing is produced by 
the presence of the individual sequence variations of the 
haplotype. Future studies will evaluate whether the 
simultaneous presence in cis of all the variations that compose 
the haplotype may influence the levels of CFTR mRNA. Some 
variant tracts (TG)mTn resulted more frequent in CF-like 
populations than in classical CF or in controls. Functional 
analysis at RNA level evidenced a higher percentage of 
anomalous splicing produced by some specific tracts. This 
correlates with the clinical phenotype of these patients. We 
evidenced some variants within the CFTR 3’-UTR. We did not 
highlight 3’-UTR sequence variations that could influence the 
binding of miRNAs currently known in the literature. Future 
studies will evaluate what effect the variations we found in this 
area can have. 
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INTRODUCTION 
 
Cystic Fibrosis (CF), also called mucoviscidosis or fibrocystic 
disease of the pancreas, is the most common lethal genetic 
disease of the Caucasian population, with a very variable 
prevalence, from 1/1350 to 1/25000 depending on the 
geographical region, and with a carrier frequency between 1/20 
and 1/80 [Farrell PM, 2008]. In the report of the Italian CF 
Registry (RIFC 2014) there is an incidence of 1 CF affected on 
4052 born alive. On this basis, the presumed number of carriers 
is calculable equal to about 1/32 in the Italian general 
population. These values are also contained in the range 
reported in studies on selected populations and of a more 
limited number (incidence: from 1/4356 to 1/2438; carrier 
frequency: from 1/33 to 1/25). Taking into consideration a 
probable underestimation of RIFC data, and also a principle of 
caution, the prevalence value of the carrier, that would seem 
representative of the Italian population, is 1/30. 
It is defined as a "multi-systemic disease" because it involves 
numerous organs and systems, including airways, pancreas, 
liver, small intestine and male reproductive system. The 
hallmarks of CF are salty sweat, poor growth and poor weight 
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gain (despite a normal food intake), pancreatic insufficiency, 
steatorrhea, malnutrition, cirrhosis of the liver, accumulation of 
thick and sticky mucus at the pulmonary level, frequent 
infections and persistent cough or shortness of breath. Near all 
affected males are not fertile due to the bilateral congenital 
absence of the vas deferens (CBAVD). Symptoms often appear 
during childhood, such as intestinal obstruction due to 
pathologic meconium ileus in newborns. On the basis of the 
symptoms, from the diagnostic point of view, differentiated 
clinical forms can be distinguished: on one side there are the 
severe polysymptomatic forms (the so-called "typical" forms 
which in this thesis will be called Cystic Fibrosis - CF), on the 
other side the lighter oligosymomatic and monosymptomatic 
forms ("atypical" forms; CFTR-pathies; CFTR related diseases 
or CFTR-RD. In this thesis will be called CF-like forms). Our 
group had also evidence that the idiopathic hyperviscosity of 
the seminal fluid (ISHV) may be, in some cases, a CF-like 
form [Rossi et al., 2004; Elia et al., 2009]. 
The disease is monogenic with mendelian inheritance and it is 
caused by mutations in the CFTR (Cystic Fibrosis 
Transmembrane conductance Regulator) gene. This gene 
encodes a protein of 1480 amino acids, which performs the 
main function of cAMP-dependent chloride channel and 
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regulator of transmembrane ion exchange of epithelial cells. 
The functionality of the protein influences, therefore, the 
composition in water and electrolytes in glandular secretions. 
An alteration at CFTR level leads to the secretion of very thick, 
viscous and sluggish mucus, with consequent obstruction of the 
main ducts. 2031 sequence variations (database CFTR1, 
December 2018) were identified in the responsible gene, of 
which about 374 were functionally characterized and 
recognized as: CF-causing (312), variants of varying clinical 
consequence (36), non CF-causing (13), variants of unknown 
significance (13) (database CFTR2, December 2018). It is an 
autosomal recessive disease, which means that the full 
manifestation of the pathology occurs only in homozygous 
individuals (same mutation on both alleles) and in compound 
heterozygote ones (two different mutations on alleles). 
Eliminating the single dosage of the gene is not enough to 
show any manifestation of the disease, but it is necessary that 
the residual functionality of the protein decreases below 50% 
to originate the symptomatology. Heterozygotes with only one 
mutation on an allele are carriers and do not have any clinical 
symptoms. Laboratory identification of these carriers results 
difficult because the biochemical tests are not enough sensitive. 
The only way to identify carriers is the genetic investigation, 
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which, however, shows a variable ability to detect CFTR 
mutations depending on the number and type of mutations 
included in the test. To date there is no decisive cure, but the 
use of some therapeutic approaches is useful to ensure a high 
standard of living to patients. In particular, the prognosis for 
CF has improved considerably: the integrated treatment 
programs have allowed, in fact, to increase the median survival 
of patients from the 25 years of the 80s to the 40 years of today 
[Wilschanski, 2013], and are supported both by the 
development of new diagnostic methods, to identify 
precociously the disease, and by the institution of specialized 
centers of reference, able to guarantee an adequate assistance to 
the patient. The research points to further improve the 
knowledge of this pathology and to find new therapies for a 
more effective treatment. They may be, in the near future, the 
solution to the inconveniences that CF causes. 
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AIM OF THE THESIS 
 
The main problems in the comprehension of CFTR-dependent 
mechanisms in CF are:  
- the great variety of the clinical forms of the disease, 
although it is monogenic;   
- the recent identification of a complex set of new related 
pathologies (CF-like forms);  
- the still uncertain genotype-phenotype correlation in this 
pathology;  
- an incomplete genetic characterization, often for strictly 
technical reasons related to the mutational search methods;  
- the limited knowledge of the mechanisms of transcriptional 
regulation of the gene, which may affect the protein levels 
and, consequently, the severity of the pathology.  
For these reasons, we conceived a research project that, in 
addition to the classical mutations of CFTR, takes under 
consideration some players of CFTR transcriptional control, 
possibly modulating CFTR mRNA levels. This may help to 
better understand CFTR-dependent mechanisms originating 
and modulating clinical severity of CF and also to provide new 
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insights about the control of CFTR expression. In particular, 
we evaluated the possible mechanisms involved in the 
transcriptional modulation through a study based on three 
experimental approaches: 1) analysis of intragenic haplotypes 
in CF and CF-like populations (CFTR-RD, CBAVD and 
ISHV); 2) analysis of variant tracts (TG)mTn and effects on the 
splicing of mRNA; 3) analysis of CFTR 3'-UTR for potential 
variants in miRNAs recognition sites. We performed the 
structural analysis on DNA by sequencing and primer 
extension and the functional analysis on RNA by reverse 
transcriptase PCR, densitometric analysis and Real-time PCR. 
The results obtained with these experiments show that there are 
some intragenic actors actively involved in the process of 
regulation of messenger RNA levels and, consequently, able to 
influence the quantity of functional protein that reaches the 
cellular membrane. In turn, this may modulate the final 
phenotype of each patient. 
A better knowledge of these aspects is very useful not only to 
understand the transcriptional activity of CFTR and the 
contribution of intragenic factors to the modulation of gene 
expression, but also to obtain an optimal definition of CF and 
CF-like clinical categories. In addition, an improvement of the 
understanding of the genotype-phenotype relationship in this 
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disease, an optimization of current screening programs and a 
development of more focused treatment strategies (customized 
for the individual patient's better-defined genotype) are 
expected. 
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1. CFTR AND CYSTIC FIBROSIS 
 
1.1 CFTR: gene, protein and mutations 
 
The CFTR is a multifunctional membrane protein that in 
vertebrates is encoded by the homonymous gene. This gene 
was first cloned in 1989 [Kerem et al., 2006] by Lap-Chee 
Tsui and his team of researchers in Toronto and it is a member 
of the superfamily of membrane transporters or ABC carriers 
("nucleotide adenine-binding cassette"). It is located on 
chromosome 7 (position 7q31.2) [Riordan JR et al., 1989] and 
consists of 27 exons (about 250 Kb). The most common 
transcript is 6128 bases long and is translated into a protein of 
1480 amino acids (Figure 1). The CFTR is under the control of 
a housekeeping promoter with a regulated time-specific and 
tissue-specific expression, established by alternative start 
transcription sites and/or by alternative splicing. The gene is 
highly expressed in various epithelial tissues of organs such as 
lung, pancreas, liver, intestine, testis, sweat glands and salivary 
glands.  
The protein is an ATP- and cAMP- dependent chloride channel 
that performs its major function on the apical membrane of 
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epithelial cells: this function is the secretion of Cl- ions in the 
colon and in the airways or its reabsorption in the sweat glands. 
The transport direction depends, in fact, on the epithelial tissue 
involved: in the respiratory epithelium and in the intestinal 
epithelium the flow goes from the inside towards the outside of 
the cells, while in the epithelium of the sweat glands it happens 
from the lumen of the gland to the inside of the cell. The 
product of the gene is, therefore, an important channel in the 
production of sweat, of digestive juices and of airway surface 
fluid. 
Figure 1. CFTR gene. The figure shows the structure of the CFTR gene 
with the 27 exons (A), the polypeptide with the various domains (B) and 
the protein model (C). [Human Genetics: Concepts and Applications by 
Ricki Lewis (1994)] 
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The structure of this glycoprotein is characterized by five 
distinct domains (Figure 2): two homologous MSD domains, 
that physically constitute the channel (each consisting of six 
transmembrane segments of hydrophobic α-helices); two 
nucleotide binding domains (NBD) for ATP, located in the 
cytoplasm; a central regulating domain (R-domain), also 
cytoplasmic, which joins the two structural units of the protein 
and which contains various phosphorylation sites [Morales et 
al., 1999]. The ion channel opens only when the regulatory 
domain is in the phosphorylated state (phosphorylation occurs 
by PKA, ie a cAMP-dependent kinase) [Morales et al., 1999] 
and the ATP is bound to the NBD domains. The terminal -NH2 
portion interacts with the 1A syntaxin, whereas the terminal -
COOH is involved in the interaction with the proteins 
containing the PDZ domain. 
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However, CFTR does not only perform the chloride ion 
channel function. Below there are the additional features of this 
protein: 
a. regulation of the function of other ion channels, such as the
EnaC (the epithelial sodium channel), the ORCC
(Outwardly Rectifying Chloride Channel), the CaCC
(calcium-dependent chloride channel), the ROMK (renal
potassium channel), the sodium/proton exchanger NHE3
and the aquaporin channel [Lubamba B et al., 2012]. These
regulations allow, directly or indirectly, the transport of
sodium, potassium, water, glutathione and bicarbonate;
Figure 2. Structure of CFTR with its domains and the fundamental 
reactions to the activity of the channel. [Sheppard et al, 1999] 
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b. pH regulation of cytoplasmic organelles (Golgi reticulum, 
phagosomes, endosomes and prelisosomes). In CF cells, in 
fact, an alkalization of these compartments has been 
observed and the glycoproteins produced show an altered 
glycosylation pattern. It has been hypothesized that these 
alterations may, at least in part, contribute to the increased 
colonization of the airways by pathogenic bacteria 
[Vankeerberghen et al., 2002];  
c. receptor for Pseudomonas aeruginosa and its consequent 
endocytosis [Goldberg et al., 2000; Pier, 2000]; 
d. regulation of innate immunity [Pier, 2000]; 
e. regulation of inflammatory processes, by action on 
chemokines and neutrophils [Vankeerberghen A et al., 
2002]; 
f. intercellular communication (gap junctions) and activation 
of enzymes [Goldberg et al., 2000]. 
The interaction of CFTR with ENaC is the most characterized. 
ENaC is located on the apical surface of the exocrine epithelial 
cells and it is responsible for the sodium intracytoplasmic 
transport from luminal secretions. The regulation of the 
transport of Cl⁻ and Na⁺ influences the homeostasis of the 
superficial liquid of the airways. It is formed by mucus and 
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periciliary fluid and performs various tasks: it guarantees 
clearance of the airways; it contains numerous antibacterial and 
anti-toxic enzymes (neutrophil proteases and protease 
inhibitors), lysozyme (disorganizing of peptidoglycans of the 
bacterial wall of GRAM+), lactoferrin and transferrin 
(antimicrobial proteins with bacteriostatic and bactericidal 
action), immunoglobulins (especially secretory IgA) and 
cytokines (IL-1, IL-8 and TNF); it protects the underlying 
epithelium from dehydration. 
The pathway of production of CFTR protein starts at the 
nucleus level, where the pre-mRNA is transcribed and 
undergoes the process of splicing of the introns; from here, it 
passes into the cytoplasmic compartment: at the endoplasmic 
reticulum level the mRNA is translated into protein which 
undergoes processing, then in the Golgi apparatus it undergoes 
further modifications and it is glycosylated at the level of the 
transmembrane domains. Finally, the mature protein reaches its 
definitive site on the apical membrane of epithelial cells. 
Mutations in CFTR gene are responsible for CF, since they 
cause an anomalous or absent production and/or function of the 
protein. The most common mutation, F508del (or ΔF508 in old 
notation), is a deletion of three nucleotides located in exon 10, 
which results in the loss of a phenylalanine in the position 508 
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of the protein. This mutation is found in two thirds (66-70%) of 
all worldwide patients of CF [Bobadilla et al., 2002]. CF 
develops when there is no allele capable of producing a 
functional CFTR protein and, therefore, it is considered an 
autosomal recessive disease. Mutations and polymorphisms are 
distributed throughout the entire coding sequence of the gene, 
in the promoter regions, in the portions of exon-intron junction 
and, in a minor part, in the introns. Modifications at the exonic 
level have consequences of variable impact on the amino acid 
sequence, while those at the intronic level may cause changes 
in the splicing process as consequence, for example, of the 
elimination of a splicing site or the creation of alternative 
splicing sites (and, therefore, of new exons). 
CFTR mutations were grouped into 6 mutational classes 
[Estvill et al., 1996; Fanen et al., 2014; Amaral, 2015], 
depending on their effects on transcription, cellular processing, 
final localization and quantitative level of functional protein 
(Figure 3). 
 Class I. These are production defects that determine the total 
lack of protein synthesis. These mutations (for example 
G542X, 3950delT, R553X, W1282X) are usually nonsense 
mutations, severe splicing mutations (which produce only 
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aberrant mRNAs), small or large deletions or insertions. 
They act by generating premature inframe or frameshift stop 
signals,  unstable transcripts and/or aberrant proteins, 
destined to have no functionality or to be rapidly degraded. 
This degradation is mediated, at RNA level, by a control 
mechanism known as NMD (Nonsense-Mediated Decay). 
The class I mutations cause, therefore, the loss of the 
chloride channel activity in the affected epithelia. 
 Class II. These are the defects of maturation of the protein
and of decreased stability and they determine an altered
tertiary structure. They are, therefore, alterations of
trafficking (membrane transport), based on the recognition
of the anomaly by the cell systems, ubiquitination and
increased degradation of the misfolded protein within the
endoplasmic reticulum. These defects of
processing/maturation severely decrease the amount of
protein in the apical cell membrane, although often with a
tissue-specificity. They can be missense mutations
(N1303K) or deletions (F508del). The class II mutations
cause the production of an abnormal protein, which is
rapidly degraded and does not reach the membrane, or
reaches it only in part often with a reduced functionality.
The clinical phenotype will usually be severe.
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 Class III. These are regulation defects that lead to an 
impairment in channel opening and in chloride transport. 
Although the CFTR protein is complete and mature and able 
to reach the apical membrane, it is not properly 
activated/inactivated by ATP or cAMP. The mutations of 
this class interfere, in fact, with the phosphorylation of the R 
domain, with the binding and hydrolysis of the ATP at the 
level of both the NBD domains and with the channel 
stimulation by the ATP. These are missense mutations 
(R553G and G551D), whose final effect is a decrease in 
functional protein activity, even though the membrane 
quantity is normal. 
 Class IV. These are the channel defects that cause a 
reduction in the transport of chloride through the CFTR. In 
this case, the protein is present on the apical membrane, but 
it is not able to adequately support the ionic flow due to a 
defect in the physical structure of the channel. This low 
conductance of chloride ions is caused by missense 
mutations (for example R117H, R334W, R234P) involving 
the domains that pass through the cell membrane and form 
the pore. This class of mutations is mostly associated with a 
moderate phenotype (alleles presenting such mutations are 
usually associated with mild pancreatic insufficiencies). 
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 Class V. These are defects of reduced synthesis or slowed
maturation. The lower production of protein is due to
mutations on the promoter or that cause splice defects, but,
unlike the class I mutations, the alterations belonging to the
fifth group do not completely abolish the correctly folded
form, since only a reduction of wild-type mRNA is realized.
In fact, since a small percentage of the transcripts may be
normal and that, therefore, a small amount of functioning
CFTR channels can be generated, the resulting phenotype
will be mild or even mono-symptomatic (as, for example, in
CF-like forms of CF). An example of variants able to
influence the splicing of the CFTR pre-mRNA is the
repetition (TG)mTn, located in intron 8, at the splicing
acceptor site of exon 9 of the CFTR gene [Chu et al., 1993;
Chillon et al., 1995; Dork et al., 1997]. In this tract there are
repeats of the TG dinucleotide followed by a variable
number of the nucleotide T: in general, it has been seen that
when there are a high number of TG repeats coupled with a
low number of T, there is a greater exclusion of exon 9 from
the messenger RNA of CFTR [Chu et al., 1993; Teng et al.,
1997]. 
 Class VI. These are the defects that cause a destabilization
of CFTR or that affect the regulation of other channels.
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These alterations affect the terminal domains of the protein, 
especially the last 70-98 amino acid residues of the C-
terminal region [Haardt M et al., 1999], and this influences 
the relationships with other proteins and their regulation. 
The mutations are nonsense or frameshift (for example 
4326delTC, 4279insA, 4271delC). Despite the biosynthesis, 
the processing and the capacity to transport the chloride by 
the truncated protein are essentially normal or only partially 
compromised, various anomalies in the regulation of many 
other proteins have been highlighted, for example of the 
epithelial sodium channel EnaC, due to lower metabolic 
stability of CFTR. 
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Only a partial correlation between variations in the gene 
sequence (genotype) and clinical manifestations of the disease 
(phenotype) exists. This means that the great variability and 
severity of the disease are related to multiple mutations in the 
CFTR gene and even more to their possible combinations. The 
determination of the relationship between genotype and 
phenotype is important, but still difficult to establish. 
Furthermore, the presence of intragenic modifiers, as specific 
Figure 3. Mutational classes of CFTR. [Ratjen et al. 2009] 
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haplotypes, and of complex alleles, that consist of two or more 
mutations in cis position, contribute to the lack of clarity of the 
genotype-phenotype relationship. Additional variability is 
introduced by the intervention of modifying genes, which can 
influence the severity of the CF phenotype through, for 
example, an alternative chloride conduction, the regulation of 
splicing, the modulation of CFTR gene expression and the 
modulation of susceptibility to infections/inflammatory 
responses [Slieker et al., 2005]. Penetrance is usually 100% in 
homozygotes or compound heterozygotes with severe 
mutations, but the gravity of the disease is variable, with even 
mild and clinically negligible clinical forms, without pancreatic 
insufficiency or with moderate respiratory failure. It should be 
also taken into account that phenotypic variability is also 
determined by numerous other factors besides those listed, 
such as random phenomena and environmental factors 
[Salvatore et al., 2011]. 
From the molecular point of view, this broad spectrum of 
clinical manifestations can be related to the amount of residual 
functional protein at the cell membrane level [Chillon et al., 
1995; Zhang et al., 2009]: there is an inverse correlation 
between the amount of residual functional protein and the 
severity of the clinical phenotype. In general, 100% of channel 
28 
activity is present in an individual with no mutation, as both 
alleles encode for a functional protein. In an individual 
carrying a severe mutation, which completely deactivates an 
allele, only 50% of functional protein will be present on the 
membrane: this residual function is sufficient to ensure an 
overall normal CFTR activity. The first clinical symptoms of 
the disease are shown when the percentage of residual function 
of the channel is less than about 10-15% [Zhang et al., 2009], 
because at this level it is possible that a mild CF-like disease, 
the CBAVD, takes place. If the amount of residual 
functionality is less than 5%, in addition to CBAVD, there will 
be a further reduced chloride transport, with an amount of 
NaCl in the sweat higher than normal, then a positive and 
pathological sweat test will occur. Coming down to 4.5%, lung 
infections will begin to appear; around 1% of residual function, 
pancreatic insufficiency will also happen. At this level the 
complete and most severe form of CF will be manifested, with 
pancreatic insufficiency, pulmonary involvement, positive 
sweat test and male infertility for CBAVD. 
Some mutations may cause the impairment of different aspects 
of CFTR function and many epidemiological studies show that 
different populations have different mutations [Bobadilla et al, 
2002]. The disease is more common, in fact, among the nations 
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of the Western world, but the distribution of CF alleles varies 
among individuals. The frequency of F508del carriers, for 
example, was estimated at 1:200 in the North of Sweden, in 
1:143 in Lithuania and 1:38 in Denmark. Because of this 
variability, it is very important to pay attention to the 
geographical origin of the individuals analyzed at the time of 
diagnosis, in order to choose the best panel of mutations for 
each case. The F508del affects about 10 million people in 
Europe [Bobadilla et al., 2002]. Some other mutations may 
have a frequency between 2% and 5% or are characteristic of 
some ethnic groups, such as W1282X in Jews from Central 
Europe and 3659delC in Swedes. In Italy the characteristic 
mutations are the T338I in the Sardinians, the 2183AA>G and 
R1162X in Northern Italy and a group of five specific 
mutations in Southern Italy. 
 
1.2 Physiopathology of Cystic Fibrosis 
 
The symptomatology of CF is certainly complex and variable 
and depends on the percentage of residual function of the 
CFTR channel and on the consequent involvement of various 
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organs capable of secretion, such as lung, salivary and sweat 
glands, pancreas, liver and biliary tract, deferent ducts 
[Knowles MR et al., 2002]. It is an extremely heterogeneous 
disease at the phenotypic level for what concern the age of 
onset, the clinical course and the impairment of the different 
organs. Moreover, some elements that influence the production 
or the process of the protein and, therefore, the clinical 
manifestation in each individual, such as the presence of 
various environmental factors and the interaction of CFTR with 
the so-called "modifier" genes, should be emphasized. Often, 
the symptoms are already evident in the first weeks or months 
of life, while in other cases they occur later, in adolescence or 
even adult age. 
The organs mostly involved are the lung (more than 90% of 
cases) and the pancreas (85% of cases). As consequences of the 
first aspect, airway obstruction leads to continuous bacterial 
infections, tissue damage and inflammation, up to respiratory 
failure and death; relatively to the second aspect, 
malabsorption occurs and this can lead to delays in growth in 
younger patients.  
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The main manifestations of CF concern: 
 Lungs and paranasal sinuses. Pulmonary disease is the
consequence of airway obstruction, caused by mucus
accumulation, reduction of mucociliary clearance and
chronic inflammation. Inflammation and infection cause
injury and structural changes in the lungs, leading to a
variety of symptoms: in the initial stages, incessant cough,
Figure 4. Clinical manifestations of Cystic Fibrosis. [Kliegman, Robert; 
Richard M Kliegman (2006) Nelson essentials of pediatrics, St. Louis, Mo: 
Elsevier Saunders] 
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abundant production of sputum and reduced lung capacity 
are common conditions (many of these symptoms occur 
when bacteria, which normally inhabit dense sputum, grow 
out of control and cause pneumonia); in the following 
phases, the pathologies of the main airways (bronchiectasis) 
further aggravate the difficulties in breathing. The 
respiratory system presents evident histological alterations, 
such as hyperplasia and hypertrophy, at the level of the 
tracheobronchial glands, and this inevitably leads to 
bronchial obstruction. Other symptoms include: cough with 
blood (hemoptysis), high blood pressure in the lungs 
(pulmonary hypertension), heart failure, difficulty obtaining 
oxygen (hypoxia) and respiratory failure. Staphylococcus 
aureus, Haemophilus influenzae, Pseudomonas aeruginosa, 
Burkholderia cepacia, Candida albicans and Aspergillus 
flavia are the most common organisms that cause severe and 
frequent pulmonary infections in patients with CF, because 
they find a fertile place to develop and grow in the wet and 
rich of mucus environment of the sick lungs. In addition, 
this thick and viscous mucus is not easily eliminated from 
the airways and stagnates, creating a beneficial situation for 
opportunistic bacteria, which are not eradicated despite a 
strong inflammatory reaction. This inflammatory process 
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then leads, with the passage of time, to the progressive 
destruction of the lung. In addition to typical bacterial 
infections, patients usually develop other types of lung 
diseases: among these, the allergic bronchopulmonary 
aspergillosis, in which the response to the common fungus 
Aspergillus fumigatus causes a worsening of respiratory 
problems, or the infection with Mycobacterium avium 
complex (MAC), a group of bacteria related to tuberculosis, 
which can cause lung damage and do not respond to 
common antibiotics. The mucus present in the paranasal 
sinuses is equally thick and can also cause obstruction, 
resulting in infection. This can cause facial pain, fever, nasal 
discharge, headache and increase breathing difficulties. 
Infections of the paranasal sinuses are usually treated with 
prolonged cycles of antibiotics. Subjects with CF may 
develop excessive growth of nasal tissue (nasal sinus 
polyposis), as well as chronic rhinitis and pansinusitis. The 
development of nasal polyps can seriously limit the flow of 
air through the nose, and over time it can even reduce the 
sense of smell. The impairment of the respiratory system is 
present in almost all patients with the severe classical 
disease and cardiorespiratory complications are the most 
common cause of death (about 80%). 
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 Exocrine pancreas. The pancreas is physiologically
responsible for providing digestive juices that help break
down food. In the affected subjects, however, the exocrine
secretions of this organ are made of a thicker and more
viscous mucus, whereby there is a stagnation of pancreatic
juices and the formation of cysts, with a fibrosis around the
ducts (from here the name of the pathology). As a result, the
latter are eventually obstructed and the movement of
digestive enzymes in the duodenum is blocked, causing
irreversible damage to the pancreas and often resulting in
painful inflammation (pancreatitis) with destruction of the
acinar tissue and parenchymal fibroadipose infarction. In the
most severe and advanced cases, the pancreatic ducts appear
even atrophic. The lack of digestive enzymes leads to
difficulties in the absorption of nutrients, in particular of
fats, with their subsequent excretion in the stool
(steatorrhea). This disorder is known as “malabsorption”
and leads to protein-caloric malnutrition and poor growth.
Individuals with CF also have difficulty in absorbing the fat-
soluble vitamins A, D, E, K and this can result in night
blindness, xerophthalmia, neuropathies, asthenia, osteopenia
and osteoporosis, anemia and coagulopathy. The exocrine
pancreatic insufficiency occurs in the majority (about 85%)
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of patients and it is mainly associated with severe mutations 
of the CFTR gene, in which both alleles are completely non-
functional. The replacement therapy with pancreatic 
enzymes allows to correct it and to avoid malnutrition. 
 Intestine. The meconium ileus is an intestinal obstruction of 
the newborn, which is unable to excrete feces, and it occurs 
in 5-10% of newborns with CF. Meconium can completely 
block the intestine and cause a serious condition. Another 
very common condition (about 10% of affected children) is 
the protrusion of the rectal internal membrane (rectal 
prolapse) that is caused by an increase in fecal volume, 
malnutrition and increased intra-abdominal pressure caused 
by coughing. Pictures of intestinal sub-occlusion (Distal 
Intestinal Obstruction Syndrome or DIOS), due to the 
presence of fecal masses, can arise in adolescence and adult 
age. In addition, people with CF often complain of 
heartburn, intestinal blockage from intussusception and 
constipation. Adult patients may also develop distal bowel 
obstruction due to thickened feces. 
 Liver. Dense secretions also involve the liver, because the 
bile, secreted to aid digestion, results more viscous for the 
reduced functionality of CFTR expressed in cholangiocytes 
and can block the ducts and cause liver damage, as well as 
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impair digestion. Over time, this can lead to the 
development of gallstones in the gallbladder and in the bile 
ducts and to scars and nodularities in the liver (cirrhosis). 
Among the most important consequences there is also the 
fact that the liver cannot clear the blood from toxins and 
does not synthesize important proteins, such as those 
responsible for blood coagulation. 
 Endocrine system. The pancreas contains the Islets of
Langerhans, which are responsible for the production of
insulin, and damages to this organ can lead to the loss of
insular cells, resulting in a form of insulin-dependent
diabetes, Cystic Fibrosis Related Diabetes (CFRD). This is
one of the most important non-pulmonary complications of
the disease, with late onset, and affects 15-20% of the
affected adult population. CFRD presents characteristics
mixed with type I and II diabetes and the main risk factors
for its onset are female sex, longevity, pancreatic
insufficiency, homozygosity for F508del and corticosteroid
therapy. Its most common complications are the
microvasculopathy: retinopathy, neuropathy and
nephropathy. The only recommended treatment consists of
insulin injections. Furthermore, the low absorption in the
diet of vitamin D, due to malabsorption, can lead to
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osteoporosis, since it is involved in the regulation of 
calcium and phosphate. People affected often develop the 
so-called Hippocratic fingers (also called clubbing), due to 
the low oxygen content in their tissues. 
 Reproductive system. Infertility mainly affects men, 
although female infertility cases have been reported in CF 
patients. At least 97-98% of affected men are infertile, but 
not sterile (they can have children with assisted procreation 
techniques). The main cause of infertility in men is the 
CBAVD (vas deferens normally connect the testicles to the 
penile ejaculatory ducts). In practice an obstruction of the 
lumen of the vas deferens is carried out that is a mechanical 
obstruction of the spermatic transport system, capable of 
rapidly provoking bilateral atresia, but potentially there may 
also be other problems that can cause azoospermia, 
teratospermia and oligoastenospermia. The reduced female 
fertility is less documented. Some women have difficulty in 
procreation due to thickening of the cervical mucus 
[Kredentser et al., 1986] or because of malnutrition and, in 
severe cases, the latter stops ovulation and causes 
amenorrhea. 
 
38 
1.3 Diagnosis and treatment 
Because of the wide range of signs and symptoms, the 
diagnosis of CF is particularly difficult, especially during 
childhood. On the other hand, however, an early diagnosis, 
able to detect pancreatic insufficiency, to prevent 
complications such as malnutrition and to allow timely 
treatment of lung infections, improves both duration and 
quality of life of patients. Therefore, for a correct diagnosis of 
CF, it is very important to carry out combined biochemical, 
genetic and clinical diagnostic investigations. A faster 
diagnosis also allows the early selection of couples with high 
genetic risk associated with subsequent pregnancies. For these 
reasons, neonatal screening programs have been activated 
around the world. 
In neonatal screening programs, the first test to be performed is 
the evaluation of the blood concentration of immunoreactive 
trypsin (IRT) in all newborns: in children with CF, the blood 
trypsin is higher than a threshold (depending on the screening 
protocol) and this fact is due to pancreatic suffering, even in 
absence of secretive insufficiency. Trypsin levels may be 
increased, however, even in individuals who have only one 
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mutated copy of CFTR (that is in carriers) and, in rare cases, in 
those ones with two normal copies of the gene (the unavoidable 
false positives of screening programs). Moreover, it has been 
shown that, in addition to newborns with CF, these screening 
programs also select CF-like neonates. So, this test is certainly 
simple to perform but, as every screening programs, shows 
optimal diagnostic sensitivity but reduced diagnostic 
specificity. Furthermore, most countries do not perform routine 
screenings at the time of birth and, as a result, most people are 
diagnosed only after the manifestation of symptoms. 
Infants with an abnormal trypsin dosage (hypertripsinemia) are 
submitted to the sweat test, for the evaluation of the 
concentration of chloride ions, to assess the diagnosis of CF. 
The sweat test (TS) [Gibson and Cooke, 1995] involves the 
application of a drug (pilocarpine) that stimulates sweating 
(ionophoretic stimulation) in the sweat glands of the forearm. 
The resulting sweat is collected on a paper sheet or in a 
capillary tube or on previously weighed gauze and analyzed for 
values of chloride. To date, the TS is the diagnostic test of 
reference, in terms of sensitivity and specificity, for the 
diagnosis of CF, since it is able to measure, in a reproducible 
and rapid way, the defect of functioning of the CFTR 
membrane protein: the test measures the event closest to the 
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basic defect of the disease, which, in the sweat glands, results 
in high concentrations of chloride in the sweat. A chloride ion 
concentration higher than 60 mEq/L leads to the diagnosis of 
CF; an intermediate (or "borderline") concentration, between 
40 and 60 mEq/L, is indicative but not diagnostic for CF; a 
concentration lower than 40 mEq/L indicates a negative test. 
Up to 6 months of age, the normal chloride cut-off should be 
lowered to 30 mEq/L. At least two positive tests are needed to 
confirm the diagnosis of the disease. Unfortunately, around 
10% of sweat tests can be false positive. In fact, TS is also 
positive in several other diseases. In addition, some CF 
subjects and many CF-like ones have a borderline or even 
negative test. Pancreatic functionality, often impaired in CF 
patients, is assessed by determination of steatorrhea or dosage 
in the feces of pancreatic digestive enzymes such as 
chymotrypsin and elastase. In some cases the measurement of 
the nasal transepithelial electrical potential difference and/or of 
the intestinal chloride flow appears to be useful additional 
diagnostic procedures. 
Taking into account the high variability of the manifestations 
of this disease, it is clear that no laboratory practice alone is 
able to provide a complete and secure diagnosis of CF. The 
screening programs, therefore, have been made more reliable 
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thanks to the genetic analysis of CFTR and to the identification 
of significant mutations in this gene. The various techniques, in 
this case, allow not only the identification of the affected 
patients, but also of the carriers. An example of the application 
of this type of analysis can be found in prenatal diagnosis. In 
fact, couples who are expecting a baby or who are planning a 
pregnancy can investigate the mutations of CFTR gene, in 
order to determine the risk that their child may have CF. The 
test is typically performed first on parents and, if the risk is 
high (both carriers), investigations are carried out on the fetus. 
In some protocols, the survey is initially performed on only one 
parent, both because the test is expensive and because the 
negativity of one parent is able to decrease the risk for an 
affected baby. Thus, if a mutation is detected in the first parent, 
the tests are carried out on the other one to calculate the risk of 
the couple. The reduction of the costs of genetic tests and the 
need to reduce reproductive risk, however, suggest an 
evolution towards the contemporary investigation of both 
parents. CF can derive from many different mutations and the 
genetic tests are not able to investigate all of them; therefore, a 
negative genetic test does not guarantee that the unborn child 
will not be affected, but it reduces the risk proportionally to the 
frequency, in the regions of origin of the family, of the 
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mutations investigated. Despite the numerous problems related 
to mutational search in CFTR, namely the fact that the 
mutations are various and heterogeneous, that the analysis 
differs according to the geographical area and that some 
sequence variations are not included in the commonly used 
panels, the difficulty of distinguishing between variants 
causing and non-causing disease, several efficient approach for 
genetic assessment exist. For this purpose, a widely accepted 
approach is the multistep one, with various levels of molecular 
analysis, which are distinguished for different execution times, 
use of different technologies, costs, sensitivity and specificity. 
The various levels and their applications are listed below, while 
the table (Table 1) shows the most common techniques related 
to each level of analysis. 
o First level analysis: it uses targeted methods to search for 
known specific mutations. The first level genetic analysis 
consists in the search of the most frequent mutations in the 
population and generally it is the most used method. Mainly 
commercial kits are used, expensive but also quick and 
reproducible. They allow to analyze a uniform mutation 
panel in different laboratories. Therefore, the first level tests 
show a rather limited diagnostic sensitivity since they allow 
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the identification of only known and frequent mutations; 
they are not very suitable if the mutations sought are 
specific for a geographical area. Moreover, they have little 
diagnostic utility in the analysis of subject presenting CF-
like forms, with borderline clinical and/or biochemical 
values and specific mutations usually not included in 
commercial panels. 
o Second level analysis: it is characterized by methods that 
allow to examine large regions of the gene, to search for any 
type of mutations, even previously unknown. These systems 
usually allow the recognition of sequence variations in all 
the coding regions, in the adjacent intronic regions (those 
that may influence splicing) and in the proximal 5'-flanking 
of the CFTR gene. Thanks to technological improvements 
and to cost reduction, the Sanger sequencing and the "New 
Generation Sequencing" (NGS) are the most used methods, 
in place of other obsolete scanning approaches. However, no 
mutational scanning technique currently used for diagnostic 
purposes is able to detect all existing CFTR mutations. 
About 3% of the mutated alleles, in fact, present mutations 
that are not easily identifiable even by extensive sequencing 
protocols. The second level tests are characterized, 
therefore, by a greater, though not complete, sensitivity, 
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identifying known or even not previously described 
mutations. Moreover, their use raises the problem of the 
interpretation of the new sequence variations found: while 
mutational panels are usually designed to include only 
CFTR mutations that cause disease, with the scanning 
procedures we also include changes in the sequence not still 
characterized from the functional point of view and this fact 
complicates the genetic counseling. 
o Third level analysis: it allows to study the mutations that
escape the first and second level, that are rare gene
rearrangements (for example large deletions), fully intronic
mutations not adjacent to exons and those ones in the distal
5'-flanking and in the 3'-UTR. As already mentioned, in 3%
of affected subjects the mutations responsible for the disease
can’t be identified, despite the analysis of all coding
portions and of the splicing regions of the CFTR gene. Since
the rearrangements involving deletions/duplications of
single or multiple exons usually escapes to this type of
analysis, it is reasonable to suppose that the presence of
insertions, duplications or deletions in CFTR is
underestimated and can account for at least a part of those
alleles not characterized. These investigations are
commonly performed using MLPA (Multiplex Ligation-
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dependent Probe Amplification), which is a procedure based 
on the use of probes that are amplified, in a PCR reaction, in 
a target-specific manner: each probe, in fact, is constituted 
by two oligonucleotides, which hybridize adjacent 
sequences on DNA and which are ligated only in presence 
of the target. There is also the possibility to study mRNA 
usually obtained from nasal epithelial cells with the 
brushing technique. This analysis is able to identify even the 
fully intronic mutations that alter the correct splicing of the 
CFTR gene; furthermore, it allows to highlight the great 
genetic rearrangements, provided that the mutation does not 
cause the missing expression of the transcript. The use of 
genetic analysis up to the third level allows to reach a 
diagnostic sensitivity (detection rate) of genetic tests in CF 
of about 98%. 
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The practical application of this multistep approach changes 
according to its use in subjects with suspected disease for 
diagnostic purposes or in subjects of the general population to 
reduce the genetic risk. In the first case it is reasonable to move 
progressively through the levels until you find two mutations 
Table 1. List of the most common techniques related to each 
level of CFTR genetic analysis. 
Genetic analysis of CFTR gene Techniques
First level analysis
1
Multiplex analysis RDB or OLA or 
ARMS of the most frequent mutations 
(commercial kits)
2
Specific analysis for the mutation of 
the family (in case the mutation of the
family is known and not included 
among those detected in the kit)
3
Mini-Sequencing for the analysis of 
single mutation sites
Second level analysis
4
D-HPLC or DGGE analysis (almost no 
longer used)
5
Sanger Sequencing or NGS for the
entire coding portion and of the exon-
intron junctions of CFTR gene
Third level analysis
6
MLPA or QMPSF analysis for the
identification of genetic 
rearrangements
7
Study of the mRNA of CFTR gene
extracted from nasal epithelium
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of CFTR on different alleles. If no mutations are found (or 
even if only one mutation is not found) even at third level, the 
genetic test contributes to a sensible exclusion of diagnosis of 
CF. On the contrary, in the second case, since it can be difficult 
to apply all levels of mutational search to each subject to check 
its carrier status, an appropriate residual genetic risk is usually 
chosen and the mutation search is performed with a suitable 
panel of mutations. Following the above considerations, it can 
be said that the often incomplete genetic characterization of CF 
and CF-like patients may often be due to technical limitations 
and constitutes the major obstacle to the understanding of the 
genotype-phenotype relationship. Although the techniques 
have progressively evolved, becoming increasingly more 
sensitive and effective, the situation still remains complex for 
CF-like forms, characterized by mutational patterns that are 
different from those of the classical forms of CF and with a 
definition of the diagnosis often not clear. 
Although there is not yet a definitive cure for CF, currently 
there are different types of treatment, which concern all the 
clinical aspects and the complications related to this disease. 
These approaches, in addition to ensure that most patients will 
reach adulthood, allow them to spend an existence less and less 
burdened by the damage of the pathology. However, the 
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management of the condition must be protracted throughout the 
life of the individual and is aimed at maximizing the 
functionality of the organs and, consequently, the quality of 
life. Among the most used treatments we have to remember: 
1. Encouragement to a good nutrition. The diet must be high
calorie and high in fats, to compensate for malabsorption,
and in proteins, to guarantee normal growth. In the event of
a deficiency, supplementation of fat-soluble vitamins,
essential fatty acids, B12, salts and iron is also required and
complications (for example diabetes) should be treated in a
specific way.
2. Additional therapy for pancreatic enzymes. In case of
pancreatic insufficiency, it is also important to administer
replacement enzymes appropriately, based on digestion and
on absorption of ingested fats.
3. Active lifestyle. Respiratory physiotherapy is one of the
most widely used practices. It is already started during the
early stages of the disease because it allows to improve lung
ventilation and to effectively eliminate secretions.
4. Hydration of the mucus. Some compounds with osmotic
effect are able to recall water from inside to outside of cells.
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In this way the mucus is more hydrated and slides more 
easily along the lungs, freeing them. 
5. Treatment of airway infections. The most consistent aspect 
of CF therapy is the limitation of lung injury caused by 
dense sputum and subsequent infections. First, the therapy 
tries to prevent infections by eliminating the thickened 
mucus that obstructs the airways and by following 
appropriate hygiene rules; instead, to treat chronic and acute 
infections in progress, antibiotics administered 
intravenously, inhaled and oral, accompanied by anti-
inflammatory drugs, are prescribed. 
6. Psychological support. Both the patient and the family must 
be followed carefully, especially since the disease often 
manifests itself at an early age, it leads to serious problems 
in everyday life and aggressive therapies are needed to 
counter it. 
7. Pregnancy support. Also in the particular case of a 
pregnancy planning, couples must be helped, whether they 
have already had a sick child or if one of the parents is 
affected (in particular the father): in the first case we use 
molecular biology techniques to calculate the genetic risk, in 
the second one we can intervene, if possible, with assisted 
reproduction practices. 
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8. Lung transplantation. This practice is recommended only
when pulmonary function is expected to decline to the point
where assistance with mechanical devices, due to respiratory
failure, is required or when patient survival is threatened.
Contrary to the past, the most modern protocols are anyway
oriented to include patients in good condition in the
transplant list without waiting for an excessive decline in
lung function. In fact, it has been shown that, in this way,
the short and long term outcomes of the transplant are much
better. It is a bilateral lung transplant. Although single lung
transplantation is possible for other conditions, individuals
with CF require replacement of both lungs: the remaining
lung may, in fact, contain bacteria that will infect the new
transplanted one. A pancreas or liver transplant can be
performed at the same time in order to relieve liver deficits
and/or diabetes.
9. New therapies. They consist essentially of mutation-specific
therapeutic approaches and gene therapy. The first ones
employ particular small molecules that correct the
functional defect induced by the specific mutations of the
CF, targeting directly the defective protein, and are designed
according to the belonging mutational class of the mutation
itself [Wilschanski M, 2013; Wilschanski M et al., 2011].
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Mutation-specific pharmacological therapies are now a 
therapeutic reality, already in use on patients, for a limited 
number of mutations. In fact, we already have two 
mutational class-specific treatments: the Ivacaftor, a 
potentiator that facilitates the opening of the Cl- channel in 
the cell (effective on the so-called mutations of gating), and 
the Orkambi, a combined therapy of a corrector 
(Lumacaftor) and a potentiator (Ivacaftor), effective also on 
those mutations with a defective maturation as, for example, 
the F508del (although with a limited efficacy in respect to 
the treatment with potentiator); the extension to an 
increasing number of mutations is now in place and this fact 
will allow the mutation-specific therapy to evolve in a 
patient-specific therapy in the future. Instead, gene therapy 
aims either to introduce the entire normal gene into the 
airway cells (gene augmentation) or to perform the specific 
correction of the mutation at the genomic DNA level (gene 
editing). At moment, this last approach is the most advanced 
genetic medicine approach for the disease, because the 
correction could be more stable over time and could reach 
physiological level of protein functionality; however, the 
quantitative level of correction is very low and this solution 
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is still under development in laboratory, requiring a longer 
period of time to be effectively transferred to patients. 
 
1.4 Cystic Fibrosis and CF-like clinical forms 
 
CF is a multi-system pathology with a chronic and progressive 
trend. It is usually associated with chronic 
bronchopneumopathy, exocrine pancreatic insufficiency (PI), 
high concentrations of chloride and sodium in the sweat, 
familiarity with the disease, male infertility. These events are 
typical of what is commonly called the "classical" form of CF 
and, in this case, the diagnosis is clear (thanks to both the 
clinical manifestations and the various laboratory tests already 
mentioned). 
The different level of functional impairment of the CFTR 
protein and the different deficit of the various affected 
apparatuses, however, originates a wide phenotypic variability, 
with clinical pictures that differ depending on the organs 
involved, the severity of the induced lesions and the age of 
onset of the symptomatology. The so-called "non-classical" 
forms may originate, characterized by a more complex and 
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often late diagnosis, since the symptoms are different and can 
only be detected in the juvenile-adult age. They can manifest 
themselves as mono-symptomatic or oligo-symptomatic forms, 
characterized by a normal function of the exocrine pancreas 
(PS), even in the presence of the typical respiratory 
impairment, and this incompleteness makes their identification 
more difficult. The common clinical features of these CF-like 
forms are the following: they are oligo or mono-symptomatic; 
the symptoms may start from infancy, but the disease becomes 
clinically significant only after several years (usually after 10 
years of age); survival reaches adulthood; there are chronic 
diseases of the respiratory system, but with pancreatic 
sufficiency; the sweat test is less than 60 mmol/l. In recent 
years, new and in-depth knowledges in the 
genetic/biomolecular field have allowed us to classify as CF-
like forms atypical clinical pictures characterized by this 
nuanced respiratory symptomatology or clinical situations in 
which there is even only one of the typical manifestations of 
CF: some examples are chronic pansinusitis, nasal polyposis, 
biliary cirrhosis and recurrent pancreatitis of undefined 
etiology, portal hypertension, hypochloraemic alkalosis, 
glucose intolerance or non-type I diabetes in adolescents, 
cholelithiasis at a young age [Kerem et al., 2006]. Among the 
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most common CF-like forms there are: minor pulmonary 
diseases (bronchiectasis and chronic bronchitis); idiopathic 
chronic pancreatitis (ICP); male infertility due to CBAVD; 
male reduced fertility due to ISHV. All these categories of 
patients are associated to various mutations of the CFTR gene. 
Patients with mild lung diseases, such as bronchiectasis, have 
milder airway symptoms than those of the classical form, 
although Pseudomonas Aeruginosa infections are common also 
in these individuals. The disease manifests itself, in this case, 
in old age and there is no pancreatic insufficiency, with sweat 
test in the norm or borderline. The lower severity of this form 
could be explained by the fact that often such subjects present a 
"severe" mutation on a gene allele and a "mild" mutation on the 
other one. CF is often associated also with ICP: a lot of patients 
with pancreatitis have mutations on both alleles of the CFTR 
gene [Noone and Knowles, 2001]. The difference with those 
affected by the classical form of CF is that the manifestations 
at the level of the pancreas arise, in this case, only in 
adulthood, while in the previous ones the functionality of this 
organ is altered since birth. At the level of the reproductive 
system the most studied monosymptomatic form in men is the 
CBAVD. These subjects do not show any classic clinical 
symptoms and the sweat test is generally borderline. Patients 
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with absence of vas deferens, without other CF symptoms, 
often present also other abnormalities of the reproductive tract: 
obstructions in the epididymis, unilateral/bilateral absence of 
the seminal vesicles, cystic dilation of the rete testis [Jarvi et 
al., 1998]. The phenotype is less severe than the classical form 
because, also in this case, often a CFTR allele has a "severe" 
mutation, while the other allele a "mild" one, and these 
mutations frequently are at intronic level, altering the 
maturation process of messenger RNA. Another pathology 
related to reproductive disorders in CF is the ISHV. It is a form 
of subfertility due to an excessive viscosity of the seminal fluid 
and to a consequent reduction of sperm motility. The causes of 
seminal hyperviscosity are not yet completely clear, but they 
seem to be the result of various factors, such as the presence of 
an acute or chronic infection or inflammation of the genital 
tract or the establishment of autoimmune processes, but could 
be traced back also to sources of different types, such as 
biochemical, enzymatic and genetic alterations, like in CF. 
Thanks to our previous studies, in some cases ISHV can be 
now considered a "minimal clinical form" of CF. There are 
several prerequisites to support this statement, for example the 
fact that the secretions in CF are thick and viscous and that the 
epididymis, in which the CFTR protein is expressed for the 
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Figure 5. Detection rates at each mutational step in the clinical CF and CF-
like macro-categories. Both the allelic (A) and genotypic (B) detection rates 
at each mutational step are shown. [Lucarelli et al., J Mol Diagn., 2016] 
hydroelectrolytic balance, is the main responsible for the 
seminal viscosity, but most of all that many variations of CFTR 
sequence are present in individuals with ISHV [Rossi et al., 
2004; Lucarelli et al., 2007; Elia et al., 2009]. 
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The great variability of clinical manifestations in CF and CF-
like populations has been examined in two previous studies of 
my research group [Lucarelli et al., 2015; Lucarelli et al., 
2016]. Different mutational patterns and different detection 
rates (the frequency of alleles or genotypes fully characterized 
Figure 6. On a total of 225 different CFTR mutated genotypes identified, 
19 (8.4%) were found in at least two different  CF and CF-like population, 
whereas the remaining 206 (91.6%) were exclusive to a single population. 
[Lucarelli et al., Mol Med., 2015] 
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from genetic point of view) were evidenced between CF and 
CF-like populations. Each mutational search step is influenced 
by the genetic heterogeneity between the different populations. 
Both the allelic and the genotypic detection rates were found to 
vary greatly between the CF and CF-like populations and at 
each step of the mutational search (Figure 5). Moreover, we 
found that this genetic heterogeneity between populations is 
amplified at the phenotypical level; in fact, the same genotype 
was found in populations with different clinical profiles 
(Figure 6). We interpreted at least part of this variability with 
the possible presence of intragenic modifiers with a possible 
effect of CFTR transcriptional regulation. We assume that they 
can act as modulators when two different mutations are already 
identified (as for example in most of CF patients) or as 
causing-disease variants when only one mutation is present (as 
for example in most CF-like patients). 
1.5 Transcriptional control of CFTR expression 
As already seen, the transcription of CFTR gene generally 
produces a primary transcript of 6.1 Kb. However, on this gene 
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a various and complex transcriptional regulation is performed 
at different levels on the development of the messenger RNA. 
Here we discuss some examples of processes that influence the 
final production of the protein, both in terms of quantity and 
quality. 
I. On this gene different transcription start sites are found. 
Since the CFTR promoter has the characteristics of a 
house-keeping promoter, the use of different 
transcription start sites can support a regulation on gene 
expression that explains the time- and tissue-specific 
expression patterns seen for CFTR. Alternatively, the 
production of a functional CFTR protein can be 
influenced by tissue- and time-specific alternative 
splicing [Vankeerberghen et al., 2002]. In general, this 
gene is more expressed in airways and in secretory 
organs than in other tissues and in a variable quantity 
with the increasing of the age (CFTR is more expressed 
at birth and then it decreased during life); the regulation 
of the expression, in this case, is guaranteed by lung 
development-specific transcription factors (FOXA, 
C/EBP) and some microRNAs (miR-101, miR-145, 
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miR-384), that regulate the switch from a strong fetal to 
a very low adult CFTR amount [Viart et al., 2014]. 
II. Different spliced forms of CFTR have been detected
[Vankeerberghen et al., 2002]. Some examples of this
alternative splicing of the gene are: exon 4ˉ; exon 5ˉ (a
splice variant that is exclusively expressed in heart,
with a still unclear functional relevance); exon 9ˉ (the
percentage of non-functional CFTR may vary between
tissues: it is higher in the vas deferens than in nasal
epithelium; moreover, the overexpression of splicing
factors can modulate exon 9 skipping, as well as the
presence of alleles carrying specific (TG)mTn
polymorphism on intron 8); insertion of 119 bp of
intron 10; exon 12ˉ; TNR-CFTR (a kidney-specific
alternatively spliced form of CFTR that, as a result of
the introduction of a premature stop-codon, gives rise to
a protein that only contains the N-terminal part of
CFTR).
III. The transcriptional modulation of a gene can be also
associated to genetic haplotypes, that consist of a
combination of allelic variants along a chromosomal
segment containing closely associated loci. They are
usually inherited together and can be often typical of
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certain geographical areas. Recent studies underlined 
that the presence of specific intragenic haplotypes of 
CFTR can be also linked to particular mutations of this 
gene: this happens, for example, to the rare CF 
mutation E1104X in a study on a population of 
Tunisian patients [Oueslati et al., 2015], and can be 
useful both as a molecular method in clinical linkage 
analysis and in cases where one or both mutations of 
the disease remain unidentified. Moreover, these 
intragenic haplotypes can be associated to different 
aspects of this complicated pathology, because the 
presence of common CFTR variants often results in 
aberrantly spliced transcripts and, consequently, in 
susceptibility, for example, to chronic pancreatitis and 
CBAVD [Steiner et al., 2011]; so the determination of 
these haplotypes helps to stratify patients into high- and 
low-risk subjects, providing helpful information for 
genetic counseling.  
IV. In the last 10 years the role of miRNAs on the 
regulation of gene expression has been partially 
described. These small endogenous non-coding RNA 
molecules are able to act on RNA silencing and post-
transcriptional regulation via base-pairing with 
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complementary sequences on 3’-UTR of target 
mRNAs. miRNAs have a dual role, both as regulators 
of development and in the maintenance of homeostasis; 
however, their expression is altered in pathological 
states, such as lung inflammation and diseases like CF. 
The cause of this alteration can be an increased/reduced 
production of a certain miRNA or a mutation on the 
binding site of miRNAs on 3’-UTR (these mutations 
may modify the affinity and thus the binding of a 
miRNA to the transcript, or may cause the appearance 
of novel target sites for miRNAs thus impairing the 
levels of gene expression). In CF, in particular, it has 
been highlighted that various aspects of this disease are 
influenced by the presence of miRNAs, in fact they 
intervene in: innate immunity, both in epithelium (miR-
126 regulates TOM1) and in bone marrow derived cells 
(miR-9 is decreased in CF neutrophils and miR-126 is 
increased in CF mononuclear cells); inflammation (a 
decrease in miR-31 expression is correlated with an 
increase in IRF-1 and cathepsin S levels, while a 
decrease in miR-93 expression is correlated with an 
increase in IL-8 levels); ion conductance (miR-145, 
miR-223 and miR-494 target directly CFTR mRNA; 
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miR-433 and miR-509-3p are increased in CF; miR-
145, miR-150 and miR-451 are upregulated in adult 
lung); ER stress (ex. miR-145, miR-221 and miR-494 
target ATF6) [McKiernan and Greene, 2015]. Often, 
the intervention of miRNAs, that directly bind CFTR, 
results in a negative modulation of the amount of 
messenger in the cell; so many current therapies are 
aimed at creating anti-miRNA agents able to protect the 
CFTR mRNA from their action [Amato et al., 2014; 
Zarrilli et al., 2017]. 
V. Obviously the presence of DNAse I hypersensitive sites 
(DHS) on promoter (5’UTR) of CFTR allows the 
binding on this gene of various transcription factors, 
that perform local changes in chromatin structure and 
histone modifications. The area at the 5´UTR of the 
gene play a role in its expression because it has a high 
GC content, several potential protein binding sites and 
many transcriptional start sites. Mutations in this 
region, especially on DHS, may change the interaction 
between the gene and its regulatory factors, thus acting 
as disease-causing mutations. Moreover, these 
mutations can modify the gene expression and, 
consequently, the clinical expression of the disease at 
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different organs levels. To date, a few disease-causing 
mutations in the proximal promoter region have been 
described in CF patients [Castaldo and Tomaiuolo, 
2013]. 
VI. The elements already studied in the basal promoter of
the gene do not fully explain all CFTR expression
patterns, suggesting that other regulatory elements are
located elsewhere, outside the basal promoter, either
within the locus or in the adjacent chromatin. We talk
about the so-called “long range interactions”. In
particular, they are insulator elements, that maintain
distinct the expression domains, and may be involved in
the mechanisms that demarcate the transition between
open and closed chromatin states, so between activation
and inactivation of the transcription of the gene. When
positioned between an enhancer and promoter,
insulators block their interaction (“enhancer-blocking”
or “barrier” activity). The CTCF (CCCTC-binding
factor) protein plays a crucial role in maintaining the
enhancer-blocking activity and several CTCF-binding
sites have been characterized in many vertebrates.
However, the precise mechanism by which insulators
work is already unknown: a looping mechanism, with
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CTCF sites being bound to the nucleolus or the nuclear 
matrix has been suggested; alternatively, CTCF may 
form part of a protein complex directly involved in 
epigenetic remodelling and in histone modification 
[Blackledge et al., 2007]. The CFTR gene is flanked by 
two genes, ASZ1 (Ankyrin repeat, SAM and basic 
leucine zipper domains) on the 5’ side and CTTNBP2 
(cortactin-binding protein 2) on the 3’ side, and they 
have very different expression profiles: CFTR is 
expressed primarily in specialized epithelial cells, while 
ASZ1 is transcribed exclusively in testis and ovary and 
CTTNBP2 is highly expressed in brain, kidney and 
pancreas. In CFTR locus there are two DHS of 
particular interest, that flank the CFTR gene upstream 
at −20.9 kb (to the 5’ of CFTR gene) with respect to the 
translational start site, and downstream at +15.6 kb (to 
the 3’ of CFTR gene). These DHS possess enhancer-
blocking activity and bind proteins that are 
characteristic of known insulator elements, but the first 
one is associated with a classical CTCF-dependent 
insulator element, while the second one is independent 
of CTCF binding. In addition to the prominent site at 
+15.6 kb, other DHS are evident 3′ to the coding region 
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of the gene: in particular, there is a complex cluster of 
sites at +5.4, +6.8, +7.0 and +7.4 kb from the CFTR 
translation end point [Ott et al., 2009]. The DHS at 
+5.4 kb and +7.0 kb were observed in a variety of cell 
types, irrespective of CFTR expression; however, the 
DHS at +6.8 kb and +7.4 kb were only found in a 
restricted number of CFTR-expressing cell-types, 
including, for example, primary epididymis cells, 
suggesting that they may contain tissue-specific 
regulatory elements that participate in controlling 
CFTR-expression [Blackledge et al., 2009]. So these 
chromatin insulators that flank CFTR prevent 
interference between the regulatory elements of 
neighbour loci and maintain independent the expression 
domains, participating in a correct and regulated 
transcription of the gene. 
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2. CASE SERIES, MATERIALS AND METHODS 
 
2.1 Analyzed populations and experimental approach 
 
The populations used in this study and their composition are 
listed below: 
 A total of 424 patients (848 alleles), already diagnosed and 
followed by the CF Regional Reference Center of Lazio 
(Institute of Pediatric Clinic, Sapienza, University of 
Rome). These patients were mainly from Central Italy, 
classified according to recent guidelines in the following 4 
clinical macro-categories: affected CF with pancreas 
insufficiency (CF-PI: 222 patients, 444 alleles), affected CF 
with pancreas sufficiency (CF-PS: 106 patients, 212 alleles), 
mono- or oligo-symptomatic CF forms (CFTR-RD: 50 
patients, 100 alleles), congenital bilateral absence of the vas 
deferens (CBAVD: 46 patients, 92 alleles). These patients 
had already been examined and characterized from a 
clinical, biochemical, microbiological and genetic point of 
view. 
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 60 sub-fertile subjects (120 alleles) with hyperviscosity sine
causa of seminal fluid (ISHV), selected by the Andrology
Unit of the Department of Clinical and Molecular Medicine,
Faculty of Medicine and Psychology of Sapienza University
of Rome, analyzed in a previous research work of my group
and considered as a minimal form of CF. [Rossi et al., 2004;
Elia et al., 2009]
 119 normospermic (NORMO) subjects (238 alleles),
selected by the Andrology Unit of the Department of
Clinical and Molecular Medicine, Faculty of Medicine and
Psychology of Sapienza University of Rome, used as a
negative control and also already characterized by the
genetic point of view.
 102 male and female subjects (204 alleles) belonging to the
general population (GEN), consisting of both blood donors
and healthy partners of couples received at the CF Regional
Reference Center of Lazio, Department of Pediatrics and
Infantile Neuropsychiatry, Faculty of Medicine and
Dentistry of Sapienza University of Rome, used as a further
negative control and already analyzed in this laboratory.
The experimental approach we have devised for this study is 
based on three kinds of analysis and explores three 
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corresponding possible intragenic CFTR modulators, already 
previously mentioned: intragenic haplotypes and the individual 
functional effect of each of the comprising variant; variant 
tracts (TG)mTn and their effect on the splicing of CFTR 
mRNA; 3’-UTR for potential recognition sites of miRNAs.  
a) The intragenic haplotypes analysis derive from a previous 
study, carried out by my research group, in which 8 markers 
of CFTR gene were selected, specifically 6 SNPs and 2 
repetitions: 125G/C (rs1800501), 875+40A/G (rs1800502), 
(GATT)n, 1001+11C/T (rs1800503), (TG)mTn, 1540A/G 
or M470V (rs213950), 2694T/G (rs1042077), 4521G/A 
(rs1800136). In this study their experimental study was 
completed. They were examined in all the populations, both 
in targets and in controls, on DNA, through MiniSequencing 
for the SNPs and Cycle Sequencing for the repetitions. With 
this analysis we obtained all the possible combinations of 
variants of each marker and evaluated the frequency of the 
haplotypes in each population. Then, these sequence 
variations were also studied individually from a functional 
point of view, through RT-PCR, to evidence any unusual 
forms of splicing. 
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b) The polymorphic tract (TG)mTn varies from one subject to
another: in fact, at the level of intron 8, we can have a
variable number of TG dinucleotide (from 9 to 13) followed
by an equally variable repetition of T (T3, T5, T7, T9; we
also analyzed a rare T6  repetition). It regulates the splicing
of exon 9: in general, a high number of TG repeats followed
by a low number of T repetitions has been seen to promote
the exclusion of exon 9 from the transcript. So we studied
this variant tract in our patients through Cycle Sequencing
on DNA to evaluate the frequency of each (TG)mTn in each
population. Then we decided to study these tracts also from
a functional point of view on RNA, using RT-PCR,
densitometric analysis and Real-time PCR; in this way it
was possible to identify the abnormal splicing forms and to
quantify them by the calculation of the percentage of both
wild-type and mutated mRNA.
c) The CFTR 3-’UTR was included in this study to evaluate
the sequence variations that could influence the action of
miRNAs. In fact, if the binding site of a miRNA on the 3'-
UTR of the CFTR gene is altered by a sequence variation, it
is possible that the miRNA binding and, consequently, the
amount of mRNA, will be changed. So, initially, we carried
out a bibliographic, bioinformatic and database research,
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whose purpose was to highlight which are the so far known 
miRNAs able to bind the 3'-UTR of CFTR; then we 
examined all the sequence of 3’-UTR (1557 bp) through its 
partition in five overlapping zones (≃400 bp for each one) 
(Figure 7), design of specific primers and Cycle Sequencing 
on DNA. This analysis did not concern all the subjects 
previously listed, but only patients with specific 
characteristics. 
As regards the basic genetic analysis, all populations had 
already been analyzed for the main mutations and genetically 
characterized before this work. My experimental contribution 
of this thesis was, therefore: 
 the completion of the structural analysis of intragenic 
haplotypes and variant tracts (TG)mTn, for a total of 250 
patients on 484. The 221 control subjects (NORMO and 
GEN populations) were already analyzed; 
 the complete bibliographic and structural analysis of CFTR 
3’-UTR; 
 the complete functional analysis of the individual variations 
included in the haplotype; 
 the complete functional analysis of the splicing of variant 
tracts (TG)mTn; 
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 the complete setting up and all the analysis with Real-time 
PCR. 
 
 
 
 
2.2 Extraction and quantification of DNA and RNA 
 
Genomic DNA was extracted from 
whole blood (only in some cases 
from sperm pellets) collected in tubes 
with EDTA, using the kit QIAamp 
DNA Blood Midi Kit (Qiagen), 
which exploits a chromatographic 
system on single-use columns. The 
quantification and purity of the 
extracted DNA was evaluated 
through the spectrophotometric 
reading of the absorbance at 260/280 
Figure 8. Phases of the RNA 
extraction procedure. 
Figure 7. Schematic representation of the five overlapping zones of CFTR 
3’-UTR. In red we indicated the points on which known miRNAs binding 
sites were found. 
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nm or the use of relative fluorescence given by Qubit 
Fluorometer (Invitrogen). All the extracted DNA were then 
brought to the concentration of 50 ng/μl and a 10 ng/μl diluted 
aliquot was made; it corresponds to the concentration usually 
used in the amplification protocol. 
The RNA was extracted from nasal epithelial cells, obtained 
through the "brushing" technique [Ramalho As et al., 2004], or 
from stem-like epithelial cell cultures of CRC (conditionally 
reprogrammed cells) [Liu et al., 2012; Suprynowicz et al., 
2012] derived from nasal epithelium of CF patients, in 
collaboration with the Higher Institute of Health. The sampling 
consists in the introduction of a stick, whose end is endowed 
with bristles, in the nasal cavities for a depth of about 3 cm. 
Once inserted, it is rotated 360° in both directions, in order to 
obtain a quantity of cells suitable for the analysis; it is 
necessary to brush both nostrils. The brush used is sterile and 
has a thickness of 2,5 mm. After collection, it is placed inside a 
2 ml eppendorf containing 990 μl of RLT buffer (Qiagen), that 
is a lysis buffer and is the first one used for RNA extraction 
procedure; to this, 10 μl of β-mercaptoethanol are added, and 
subsequently the cells are frozen at -80°C. The next day the 
extraction is performed using RNeasy mini kit (Qiagen), which 
allows to extract the total RNA from cell pellets. RNeasy 
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technology simplifies the isolation of total RNA, combining 
the use of guanidine thiocyanate for cell lysis with purification 
through the use of single-use columns with silica membrane, 
ideal for obtaining a high level of RNA purity. The system 
used is therefore a chromatographic system. The quantification 
and the purity of the extract are evaluated by 
spectrophotometry, analyzing the absorbance at 260/280 nm, or 
reading the relative fluorescence given by Qubit Fluorometer, 
while the quality of the extracted RNA is evaluated by agarose 
denaturing gel electrophoresis, which makes it possible to 
distinguish the characteristic rRNA bands. 
2.3 MiniSequencing (primer extension) and sequencing of 
the CFTR gene 
The second level investigation of CFTR gene has the function 
to investigate all the rare or unknown mutations and to identify 
possible sequence variations of pathological interest by means 
of direct sequencing (Cycle Sequencing) of genomic DNA; it 
can be used also to study variant tracts and repetitions that are 
present in the sequence. Instead, when a sequence variation is 
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already known, it is preferred to use a faster methodology, 
called MiniSequencing, that is a primer-extension reaction in 
which each primer binds in a complementary manner to the 
target, in presence of a DNA polymerase and fluorescently 
labeled ddNTPs (dideoxy-terminators): the polymerase extends 
the primer of a single nucleotide, adding a single ddNTP to its 
3' end [Lucarelli et al.,2015; Lucarelli et al.,2016]. In this 
thesis, I used the results of a previously executed first level 
analysis and completed the second level analysis, together with 
the MiniSequencing method, to study at the structural level the 
intragenic modifiers of CFTR. In particular, I analyzed the six 
single nucleotide polymorphisms (SNPs) of the intragenic 
haplotype (125G/C; 875+40A/G; 1001+11C/T; 1540A/G or 
M470V; 2694T/G; 4521G/A) using MiniSequencing and the 
two repetitions (that are (GATT)n and (TG)mTn) using a 
classical Sanger Sequencing (Figure 9). 
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The sequencing of the exons including the 8 markers that 
compose the selected haplotype, including the (TG)mTn tract, 
and of the 3’-UTR (divided in 5 zones) was performed, as well 
as the sequencing of the entire coding region and adjacent 
intronic zones. The extended analysis (amplification, 
purification and DNA sequencing) was performed in 96-well 
Figure 9. Schematic representation of the approach used for the study of 
the intragenic haplotype. On the left there is an example of amplification of 
the DNA zones of interest; on the right there are an example of peaks of 
the six SNPs included in the intragenic haplotype and obtained through 
MiniSequencing (on the top) and an example of electropherograms of the 
two repetitions included in the intragenic haplotype and obtained through 
CyCle Sequencing (on bottom).  
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format: in this way it was possible to simultaneously amplify 
all the zones of interest and analyze up to 12 samples. 
For sequencing, it is first necessary to proceed with the 
amplification of the DNA zone of interest, then to the PCR 
product purification and subsequently to the Cycle Sequencing 
reaction, from which the final products will be obtained and 
will be separated by the genetic analyzer [Lucarelli et al., 
2006]. The PCR reagents are initially assembled into a single 
master mix, not containing the pairs of primers, and this is 
subsequently divided into aliquots. Later, PCR primer pairs are 
added, so that each aliquot contains the specific primer pair for 
each zone. These aliquots are dispensed into the plate by a 
multi-channel pipettor. The DNA samples are divided into 12-
well strips and subsequently dispensed into the plate. This 
disposition makes sure that the samples and the pairs of 
primers will be crossed in such a way that in each well there is 
a single combination of primers amplifying a given zone of the 
CFTR of a specific sample. This multiwell organization was 
maintained for subsequent purification and sequencing. For the 
amplification, "external" primers are used, while for the 
subsequent sequencing reactions "internal" primers are 
employed; they are designed internally compared to the 
previous ones, in order to increase the specificity of the 
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MM PCR: 
1. H2O
2. Buffer 5X
3. MgCl2 (25 mM)
4. dNTPs (1,25 mM)
5. Go Taq Promega (5 U/μl)
6. External Primer Forward (10 pmol/μl)
7. External Primer Reverse (10 pmol/μl)
8. Sample (10 ng/μl)
x 1 
2.75 μl 
3.0 μl 
0.9 μl 
2.1 μl 
0.05 μl 
0.6 μl 
0.6 μl 
5.0 μl 
15.0 μl 
reaction. Both external and internal primers are designed in 
such a way that all known small variations in the exons and in 
the adjacent intronic zones are identifiable. The internal 
primers used in the sequencing reactions are purified by HPLC, 
in order to eliminate the background of n-1. The description of 
the single steps of this approach follows.   
2.3.1 DNA amplification by PCR 
The amplification of the samples was carried out by means of a 
PCR of the DNA segment which is subsequently intended to be 
sequenced; the reaction mix (for a single sample) is prepared as 
follows:  
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First the reaction mix is prepared; after dispensing it, 5 μl of 
each sample are subsequently added. DNA amplification is 
performed using the PTC 100™ (MJ Reasearch) thermocycler 
and the program used is as follows:  
 
 
   40 cycles  
  
 
 
 
2.3.2 Electrophoresis on agarose gel 
The amplicons are electrophoretically controlled to evaluate 
their size in number of bases (bp); 3.3 μl of amplicon together 
with 3.3 μl of Loading 2x are mixed, migrated and compared 
with a molecular weight standard (Ladder 6.6 μl). The 
verification by electrophoresis is necessary not only to check 
the amplicons, but also to rule out any contamination of the 
blank reactions. The bands are visualized on an ultraviolet light 
 95°C for 2 minutes (step of activation of 
Taq Polimerase) 
 94°C for 45 seconds (denaturation of DNA) 
 Ta° from 62°C to 54°C in TD for 1,30 
minutes (primer-specific temperature for 
pairing)   
 72°C for 4 minutes (fragment extension) 
 72°C for 7 minutes (final extension) 
40 cycles 
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transilluminator, which excites the DNA to which an 
intercalating dye (GelRed) is bound. 
2.3.3 Enzymatic purification of the amplicons 
Before MiniSequencing: The amplicons are joined in a single 
tube (2 μl from each PCR product) and are brought to a final 
volume of 15 μl with water. To these mix of amplicons, 5 μl of 
FastAp (Thermosensitive Alkaline Phosphatase, Thermo 
Fisher) [1 U/μl] and 0.1 μl of Exo1 (Exonuclease 1, Thermo 
Fisher) [20 U/μl] for each sample are added. The solution is 
incubated at 37°C for 60 minutes to remove the excess of 
primers and the non-incorporated dNTPs, and then placed at 
80°C for 15 minutes to deactivate the enzymes. 
Before Cycle Sequencing: The amplicons are purified by 
adding to the 11.7 μl left of the amplification reaction, a 
reaction mix composed of: 1.5 μl of Buffer, 1.2 μl of the 
enzyme FastAp [1 U/μl] and 0.6 μl of the enzyme Exo1 [20 
U/μl] for each sample. The solution is incubated at 37°C for 45 
minutes to remove the excess of primers and the non-
incorporated dNTPs, and then placed at 80°C for 15 minutes to 
deactivate the enzymes. This step is performed in a 96-well 
format. 
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2.3.4 MiniSequencing (primer extension) 
MiniSequencing technique allows the study of single 
nucleotide polymorphisms (SNPs) through the primer 
extension of a single fluorescent nucleotide. In this method, 
much importance is assumed by the MiniSequencing primers; 
in fact, primers with certain characteristics have been planned 
and designed for this job: 
- these primers are designed close to the mutation site and 
they must differ in length to avoid any overlap between the 
final products (a difference in length of at least 4-6 
nucleotides between successive primers is necessary): we 
reached a common temperature of annealing of 50°C; 
- in some cases, the length of the primer was modified by the 
addition at its 5’ end of a polynucleotide tail (poly-A tail), 
not homologous to the target sequence; 
- the mobility of an oligonucleotide in capillary 
electrophoresis is determined by its length, by its nucleotide 
composition and by the type of fluorochrome used: all these 
variables were taken into consideration both in the design 
phase and, experimentally, in the test phase (the effect of the 
nucleotide composition on the mobility can be not 
negligible when the primer is short); 
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- finally, the MiniSequencing primers are purified HPLC to 
avoid the appearance of unwanted products that could 
interfere with the final analysis. 
 
 
 
 
These primers, before use, are mixed together to give a mix of 
CF-SNaP primers. This mix is composed by 15 μl of primers 
(2.5 μl x 6), from the stocks at 100 pmol/μl, and 35 μl of H2O, 
for a total volume of 50 μl; so, each primer is 5 pmol/μl 
concentrated. 
Table 2. List of the six primers designed and used for MiniSequencing. In 
the first column the primers names are indicated; in the second column 
there are the relative sequences of the primers, with the poly-A tail in bold; 
in the third column the number of bp for each primer is evidenced. 
Oligo Name Sequence bp
H125G>C ATAATGGGACCCCAGCGCCC 20
H875+40A>Gback GGTTTTACTAAAGTGGGCTTTTTGAAAACA 30
H1001+11C>T
GAAAAAATGATTGAAAACTTAAGACAGTAAGT
TGTT
36
H1540A>G
ATAAATTATTAATAGGGTTTTATTTCCAGACTT
CACTTCTAATG
44
H4521G>Aback
TAAAAAAATAAAAAATAAAAAAAAAATGTC
TCCTCTTTCAGAGCAGCAAT
50
H2694T>G
TATAAATATAATATAATAATAAATATACATGG
AACACATACCTTCGATATATTAC
55
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The reaction mixture is prepared using the SNaPshot Multiplex 
Ready Reaction Mix (MRRM, Applied Biosystems), 
containing the DNA polymerase and fluorescently labeled 
ddNTPs. The reaction mix for a single sample is prepared with 
Figure 10. Schematic representation of the MiniSequencing 
technique. 
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MM MiniSequencing: 
1. MRRM
2. CF-SNaP primers mix
3. Sample (purified PCR product)
x 1 
2.5 μl 
0.5 μl 
2.0 μl 
5.0 μl 
MRRM and the CF-SNaP primers mix; finally, 2 μl of purified 
PCR product are added. 
The solution obtained is placed in the thermocycler with the 
following program:  
 96°C for 10 seconds
 50°C for 5 seconds     30 cycles 
 60°C for 30 seconds
At the end of the MiniSequencing reaction, each sample 
undergoes a further purification treatment to remove the non-
incorporated ddNTPs, that could interfere with the migration of 
the fragments of interest: for each sample an alkaline 
phosphatase treatment is carried out, in order to remove the 
phosphate groups at the 5’ end of each ddNTPs (37°C for 60 
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minutes followed from 80°C for 15 minutes as inactivation 
step).  
 
2.3.5 Cycle Sequencing 
Sanger Sequencing is based on the principle that the DNA 
polymerase is unable to extend a nucleotide sequence after the 
insertion of a dideoxynucleotide (ddNTP); the latter, an analog 
of the deoxynucleotide (dNTP), is characterized by the absence 
of the hydroxyl group (OH) also in 3', necessary to promote the 
formation of the subsequent phosphodiesteric bond. 
Each amplicon obtained by PCR reaction represents the 
template for two different sequencing reactions, performed 
with the internal primers, forward and reverse. Thus, with a 
single primer at a time, two sequencing reactions are 
performed, in which both the standard deoxynucleotides 
(dATP, dTTP, dCTP, dGTP) and the analogues fluorescents 
ddNTP (dideoxynucleotide) are mixed. The latter, once 
inserted into the polynucleotide chain in elongation, do not 
allow a further extension. 
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The sequencing reaction mix is prepared using a kit provided 
by the Applied Biosystem (ABI PRISM Big Dye Terminator 
v.1.1 Cycle Sequencing Kit), consisting of the TRRM
(Terminator Ready Reaction Mix) containing, among other 
Figure 11. Schematic representation of the  Cycle Sequencing 
technique. 
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components, a mixture of dNTPs and ddNTPs labeled with 
four different fluorescent molecules; to this mix only the 
primer, purified by HPLC and corresponding to the DNA 
strand that has to be sequenced, must be added. 
The reaction is placed in the thermocycler with the following 
program:  
 96°C for 1 minute 
 96°C for 10 seconds 
 50°C for 5 seconds              30 cycles 
 60°C for 4 minutes                                                                                          
To work in 96-well format, a single reaction mix is prepared, 
primers free, and divided into aliquots, to which the specific 
MM Cycle Sequencing: 
1. TRRM (v.1.1) 
2. Buffer 5X 
3. Internal Primer Forward or Reverse (10 pmol/μl) 
4. H2O 
5. Sample (purified PCR product) 
x 1 
0.5 μl 
1.75 μl 
0.5 μl 
3.25 μl 
4.0 μl 
10.0 μl 
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primers for sequencing are added. These aliquots are dispensed 
into the plate and, subsequently, the amplicons are added. Each 
well contains, therefore, a single combination of amplicon and 
specific primer for sequencing. Starting from an amplification 
plate, two sequencing plates can be assembled, one for the 
forward strand and the other one for the reverse. At the end of 
the sequencing cycles, the samples undergo a further 
purification process with a QIAGEN (DyeEx 2.0 Spin Kit) 
chromatographic system, to remove the labeled 
dideoxynucleotides not incorporated: in this way, the ddNTPs 
are prevented from migrating with the fragments of interest and 
creating interference in the detection.  
2.3.6 Capillary electrophoresis 
Sequencing is evaluated with electrophoretic runs through a 36 
cm long capillary. The apparatus used is the ABI PRISM 
3130xl Genetic Analyzer (Applied Biosystems) with sixteen 
capillaries and POP6 as matrix. 
After MiniSequencing: Before proceeding with the 
electrophoresis of the samples, a molecular weight standard 
labeled with a fifth fluorochrome (GeneScan-120 LIZ size 
standard) must be added; it is different from those with which 
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the ddNTPs are marked and it is specific for small fragments 
and necessary for the final analysis of the products. Capillary 
electrophoresis separates the different fragments that a specific 
software show as a series of peaks of different color; the data 
analysis is carried out using the ABI PRISM® GeneMapper 
software (Applied Biosystems): this program allows to verify 
the size of a fragment based on the migration of a molecular 
weight standard and to view which fluorescently labeled 
ddNTP was inserted. A single peak indicates that the variation 
of interest is found in homozygosis (wild-type or mutated), 
while a double peak indicates that it is found in heterozygosis. 
After Cycle Sequencing: During the electrophoretic run, the 
fluorescence signal of the different fragments, detected by the 
CCD camera present in the instrument, is converted into a 
series of peaks of different colors, generally called an 
electropherogram. The obtained electropherogram is analyzed 
with the aid of the ABI PRISM® programs Sequencing 
Analysis and SeqScape (Applied Biosystems); every single 
peak is checked and the correct nucleotide call is evaluated, 
correcting where necessary. In this way any anomalies in the 
path are identified, such as the presence of overlapping peaks 
(possible mutation in heterozygosis), irregular peaks (possibly 
due to current variations), background disturbances 
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(attributable to poor quantity of the amplicons) or insufficient 
resolution of the peaks (attributable to possible polymer 
defects). The sequence obtained is compared to the wild-type 
sequence; this allows to highlight any areas of non-homology 
within experimental sequence. 
Figure 12. Example of a project template created with the SeqScape 
software. 
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MM RT-PCR: 
1. iScript Reaction Mix 5X
2. RT enzyme
3. H2O
4. Sample (200 ng/ μl)
x 1 
4.0 μl 
1.0 μl 
10.0 μl 
5.0 μl 
20.0 μl 
2.4 Expression analysis of the CFTR gene by RT-PCR 
Retrotranscription is an in vitro 
synthesis of a cDNA conducted by 
the use of a reverse transcriptase 
enzyme. The total RNA extracted 
was retrotranscribed by means of 
the iScript cDNA Syntesis kit 
(Biorad), which consists of the 
reverse transcriptase already 
provided with RNase inhibitors, as 
well as random hexamers and a 
mixture of dNTPs. RT-PCR was performed using 1 μg of total 
RNA (for each sample) in a retrotranscription volume of 20 μl. 
As a negative control, a reaction without reverse transcriptase 
(RT) is prepared, with the same amount of RNA and of 
Reaction Mix.  
Figure 13. Schematic 
representation of the  RT-
PCR technique. 
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The reactions are then incubated in a thermocycler, according 
to a program that allows the synthesis of the double stranded 
cDNA: 
- 25°C for 5 minutes 
- 42°C for 30 minutes 
- 85°C for 5 minutes 
In order to amplify the cDNA obtained, specific pairs of 
primers are available, designed by my research group to cover 
the entire length of CFTR messenger (six overlapping 
fragments) and able to highlight the splicing of each exon 
[Auriche et al., 2010]. The fragments of CFTR cDNA analyzed 
are the following: 5’UTR-EX7 (1118 bp); EX6a-EX10 (865 
bp); EX7-EX13 (780 bp); EX11-EX15 (1142 bp); EX13-EX19 
(1141 bp); EX18-3’-UTR (1060 bp). The RT-PCR products are 
subsequently analyzed by electrophoretic run on a 1.5% 
agarose gel, to verify possible deletions/insertions and 
alternative splicing forms, observing the electrophoretic 
mobility of the amplicons and knowing exactly the expected 
dimension of each exon. In presence of an abnormal amplicon, 
we proceeded with the recovery of the amplicon from the gel 
and with the subsequent sequencing, to characterize the 
anomalies found. We also used the UVP's bioimaging and 
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analysis system “VisionWorks LS” (Life Science Software) to 
study these alterations by a semiquantitative densitometric 
analysis. This program allows to establish the optical density of 
each band. After the amplification and the electrophoretic run, 
we can visualize the bands on the gel, verify their dimension 
and calculate the percentage of both wild-type and mutated 
retrotranscribed mRNA. Bands with higher or lower molecular 
weight, in respect to wild-type mRNA, may highlight 
anomalous splicing. 
 
2.5 Expression analysis of the CFTR gene by Real-time 
PCR 
 
Real-time PCR is a method that simultaneously amplifies and 
quantifies DNA. Common methods of quantification include 
the use of fluorescent stains intercalating with double-stranded 
DNA (like in the SYBR Green method) and modified DNA 
oligonucleotides, called probes, that are fluorescent once 
hybridized with DNA and then degraded by the DNA 
polymerase during the elongation step of PCR amplification 
(like in the TaqMan method). It is therefore a quantitative 
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assay to estimate the expression levels of specific RNAs: in 
fact, the retro-transcription produces complementary cDNA, 
while maintaining unchanged the relative concentration ratios 
of the different RNA species present in the sample. In this way 
it is possible, for example, to measure the relative expression of 
a gene at a particular time, either in a cell or in a particular type 
of tissue. 
The technology we decided to apply is that of fluorescent 
probes, that are synthetic oligonucleotide constructs (20/30 bp 
long). The use of a detector probe significantly increases the 
specificity, and allows regular quantification even in the 
presence of non-specific amplification products (on the 
contrary fluorescent dyes, such as SYBR Green, reveal the 
amplification of any DNA fragment). We use 3 TaqMan probes 
(Single Tube TaqMan Gene Expression Assays) (Figure 14), 
provided by the Applied Biosystems (ThermoFisher 
Scientific), to study the variant tract (TG)mTn and the related 
splicing levels of CFTR exon 9:  
o Exon8 – Exon9: probe used to study the percentage of
CFTR mRNA with exon 9. It works when no splicing is
present.
95 
 
Exon 8 Exon 9 
Exon 8 Exon 10 
Exon 18 Exon 19 
Figure 14. Schematic representation of the approach used for the study of 
the variant tract (TG)mTn with Real-time PCR and TaqMan probes. The 
CFTR exons of interest are represented with different colors; the blue lines 
at the esonic junctions represent the TaqMan probes and their relative 
positions. 
o Exon8 – Exon10: probe used to study the percentage of 
CFTR mRNA without exon 9. It works when splicing is 
detected. 
o Exon18 – Exon19: probe used to study the total quantity of 
CFTR mRNA. It is an internal control, not related to exon 9. 
These probes are designed at the edges of exons of interest and 
they are FAM dye-labeled. 
 
 
 
 
 
 
 
An absolute quantification of the concentrations of specific 
RNAs can be carried out by producing a standard calibration 
curve; alternatively, a relative quantification can be performed 
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by comparing their quantity with respect to that of a control 
gene. Absolute quantification can use standard samples (for 
example plasmid DNA), whose absolute concentration is 
known. It must be certain, however, that the efficiency of the 
PCR is the same for all the samples. The relative quantification 
method, instead, requires the quantification of control genes or 
constitutive genes to normalize the expression of the studied 
ones. However, selecting the appropriate control genes can 
cause problems because they may not be expressed equally 
through all the unknown samples. This can be solved by 
normalizing the measurements with a set of housekeeping 
genes to avoid the possible variability. For our work we used 
an absolute reference, through the use of plasmids pCR2.1 
(Invitrogen), containing exon 9 (PL 9+) and not containing it 
(PL 9-); therefore, we created plasmid mixes with known 
concentrations of both PL 9+ and PL 9- and we constructed a 
calibration curve against which we compared the results of 
splicing of our samples. We evaluated the expression of total 
CFTR in the samples with the probe relative to Exon18 – 
Exon19, insensitive to exon 9 splicing. 
For each probe a unique mix is initially prepared and, in 
addition to the samples, a reaction blank is also used to 
evaluate that no contamination is present. All Real-time PCR 
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reactions are performed in triplicate, both for the samples and 
for the reaction blanks. The mix for each probe contains: 
FluoCycle II Master Mix for Probe (EuroClone), that is a 
specific Real-time PCR mix in which reaction buffer, dNTPs, 
MgCl2 and Taq DNA polymerase are already present; 
TaqMan Gene Expression Assay (FAM dye-labeled probe), 
that contains both the specific probe and its relative primers; 
RNase-Free Water; cDNA of interest. The final volume for 
each reaction is 20 μl.  
 
 
 
 
 
 
 
 
The Real-time PCR instrument is a Bio-Rad Opticon 2 and the 
program used is the following: 
 95°C for 5 minutes 
 95°C for 15 seconds                      
 60°C for 1 minute                                
45 cycles 
MM Real-Time PCR: 
1. Master Mix FluoCycle II 2X 
2. TaqMan probe 20X 
3. H2O 
4. Sample (50 ng/ μl) 
x 1 
10.0 μl 
1.0 μl 
8.0 μl 
1.0 μl 
20.0 μl 
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2.6 Statistical analysis 
Statistical analysis were performed on all the data reported, to 
evidence statistically significant differences between target and 
control populations.  
All data were analyzed using the ANOVA variance analysis 
test in the comparison of all the populations under 
investigation, with a p<0.05 considered statistically significant.  
For the selection of intragenic haplotypes, we use the ANOVA 
variance analysis test with Bonferroni’s correction for multiple 
tests in the comparison of all the populations under 
investigation, with a p<0.001 considered statistically 
significant. The specific analysis program used for this 
selection is “Haploview”, that is a commonly used 
bioinformatics software which is designed to analyze and 
visualize patterns of linkage disequilibrium (LD) in genetic 
data. It can also perform association studies, choosing tagSNPs 
and estimating haplotype frequencies. 
In the scatterplots, the regression curve was extrapolated and a 
correlation analysis (Pearson R correlation index) was 
performed, considered statistically significant with a p <0.05. 
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3. RESULTS 
 
3.1 Analysis of intragenic haplotypes 
 
The analysis of intragenic haplotypes was performed on all the 
seven populations under examination (CF-PI, CF-PS, CFTR-
RD, CBAVD and ISHV as populations of interest, NORMO 
and GEN as controls). Following preliminary analyses starting 
from a higher number of markers, we selected 8 markers (6 
SNPs and 2 repetitions): 125G/C, 875+40A/G, (GATT)n, 
1001+11C/T, (TG)mTn, 1540A/G (M470V), 2694T/G, 
4521G/A. Then, we obtained all the possible combinations, for 
a total of 48 haplotypes and, by means of statistical analysis, 
we highlighted those that show a significant difference in 
frequency among all the populations analyzed, for a total of 5 
haplotypes. The most common haplotype in our populations of 
interest, that we considered as “target” for subsequent studies, 
is as follows: 125G, 875+40A, (GATT)6, 1001+11T, 
(TG)10T9, 1540A, 2694T, 4521G. The same analysis allowed 
us also to highlight a control haplotype, which results, unlike 
the first, significantly more frequent in the NORMO and GEN 
populations than in the populations of interest. The control 
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haplotype is as follows: 125G, 875+40A, (GATT)7, 
1001+11C, (TG)11T7, 1540G, 2694T, 4521G. The first graph 
(Figure 15) shows the compared trend of these two haplotypes, 
based on their relative frequency in the seven populations. It is 
particularly important to underline that the target haplotype is 
present in 63% of the CF-PI alleles, in 33% of the CF-PS 
alleles, in 36% of the CFTR-RD alleles, in 20% of the CBAVD 
alleles and in 13% of ISHV alleles as compared to 6% in 
NORMO alleles and 3% in GEN alleles and, therefore, it has a 
trend that varies with the clinical condition of the population 
(in a statistically significant manner). In the second graph 
(Figure 16), the other 6 most frequent haplotypes are 
indicated, but they do not show a particular trend through the 
various populations, with frequency differences statistically 
significant only in 3 of them. 
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Figure 15. Frequencies of the target (in blue) and control (in orange) 
haplotypes in the populations under examination. 
Figure 16. Frequencies of the remaining six haplotypes in the populations 
under examination. 
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After the structural analysis, the single sequence variations that 
compose the haplotypes were studied also from a functional 
point of view. One of them is located in the 5’-flanking region 
of the CFTR gene, 3 are intronic variants and 3 are silent 
exonic variants. Consequently, they can have a functional 
effect on the expression of CFTR mRNA. We studied this 
aspect through RT-PCR and agarose gel electrophoresis of the 
cDNA tracts with the variations of interest. By this approach, 
we were able to evaluate if their presence could in any way 
influence the levels of wild-type mRNA and, therefore, the 
functionality of the protein. The photos (Figure 17) show some 
examples of comparison between the individual variations 
included in the target haplotype (left for each pair) and the 
individual variations not included in the target haplotype (right 
for each pair), in homozygosis or heterozygosis (description 
under the photos). For each tract analyzed the length of the 
cDNA fragment and the haplotype sequence variations 
considered are indicated (description above the photos). It is 
evident that the individual sequence variations included in the 
haplotype do not produce any anomalous splicing, as also 
compared with the effect of individual sequence variations not 
included in the haplotype. Therefore, they are not able, 
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individually, to cause alterations in the wild type levels of 
CFTR mRNA.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
RT+ RT- BK 
125 G/G 875+40 A/A; 
1001+11 T/T; GATT 6/6; 
125 G/C; 875+40 A/A; 
1001+11 T/T; GATT 6/7 
RT+ RT- BK 
5’UTR-EX7 (1118 bp) 
125 G/C; 875+40 A/G; 1001+11 C/T; GATT 6/7 
EX6a-EX10 (865 bp) 
875+40 A/G; 1001+11 C/T; GATT 6/7; (TG)mTn 
875+40 A/A; 1001+11 T/T; 
GATT 6/6; (TG)10T9 / (TG)10T9 
RT+ RT- BK RT+ RT- BK 
875+40 A/G; 1001+11 C/C; 
GATT 7/7; (TG)10T7 / (TG)10T7 
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2694 T/T 
RT+ RT- BK
2694 G/G 
RT+ RT- BK
EX11-EX15 (1142 bp) 
2694 T/G 
(TG)10T9 / (TG)10T9; 470 M/M 
RT+ RT- BK
EX7-EX13 (780 bp) 
M470V; (TG)mTn 
RT+ RT- BK 
(TG)11T7 / (TG)11T7; 470 V/V 
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3.2 Analysis of variant tracts (TG)mTn 
 
Before this study, we performed a preliminary experimental 
functional analysis of the variants (TG)13T5, (TG)12T7, 
4521 G/G 
RT+ RT- BK RT+ RT- BK 
4521 A/A 
EX18-3’-UTR (1060 bp) 
4521 G/A  
Figure 17. Study of the effect of the individual sequence variations of 
the target haplotype on the splicing of the corresponding mRNA tracts of 
the CFTR gene. On top of each pair of photos the tract considered, its 
specific molecular weight in bp and the variations of the haplotype that 
are found in the tract are indicated; on bottom of each pair of photos the 
variations considered are evidenced, in blue if included in the target 
haplotype (on left) and in orange if not (on right). Even if in some tracts 
more than a variation is indicated,  the functional study considered them 
always individually. 
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(TG)11T5 and (TG)12T5 that, in agreement with the literature 
data, showed a higher percentage of abnormal splicing of exon 
9. To verify if this alteration of the splicing could be partly
responsible for the pathological phenotype of the populations 
under examination, we decided to analyze (TG)mTn variant 
tracts and to calculate their frequency. The graph (Figure 18) 
shows that the ISHV, CBAVD and CFTR-RD populations 
have a statistically significant higher cumulative frequency of 
these tracts than the other subjects, in particular of the 
(TG)12T5, which causes the highest percentage of abnormal 
splicing of exon 9. These patients, which are more 
characterized by variant tracts and sequence variations with 
limited functional effect rather than classical CF mutations, 
exhibit a CF-like clinical phenotype. In contrast, populations 
with a more severe CF clinical phenotype show a lower 
prevalence of these tracts (in agreement with a higher 
prevalence of severe mutations). We also noted that CBAVD 
patients have a higher frequency of the (TG)12T5 tract, 
correlated with the greater severity of their reproductive 
pathology, compared to ISHV patients in which the (TG)11T5 
and (TG)12T7 tracts are more frequent and that show a less 
severe reproductive phenotype. 
107 
 
We decided to analyze also those (TG)mTn tracts that are not 
known to cause significant anomalous splicing in the CFTR 
gene and to calculate, also in this case, their frequency in our 
populations. The graph (Figure 19) shows that all the 
populations, both targets and controls, present a very similar 
cumulative frequency of these other tracts. Individually, the 
most frequent are: (TG)10T9 present in 66% of CF-PI patients; 
(TG)11T7 present in 59% of NORMO subjects; (TG)10T7 
present in 27% of GEN subjects. In general, however, we 
found flat and non-statistically significant results, confirming 
the fact that these tracts are probably not involved in the 
variability of CF manifestations. 
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Figure 18. Frequencies  of the variant tracts (TG)13T5, (TG)12T7, 
(TG)11T5 and (TG)12T5 in the populations under examination. 
Figure 19. Frequencies  of the other variant tracts (TG)mTn in the 
populations under examination. 
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At this point, we needed to characterize these variant tracts at a 
functional level, through RT-PCR and 1.5% agarose gel 
electrophoresis of the cDNA fragment in which exon 9 is 
present. This allowed to study how the different (TG)mTn can 
influence the processing of the CFTR mRNA and to assess the 
level of residual wild type mRNA after an anomalous splicing 
event of exon 9. We considered different genotypes, on which, 
through a specific densitometric analysis, we evaluated the 
percentage of wild-type mRNA (higher band that includes exon 
9) and mutated mRNA (lower band that excludes the exon 9) 
compared to the total mRNA. For each genotype, the analysis 
was performed on at least 3 biological replicates and for each 
of them we considered at least 3 analytical replicates. In the 
figure below (Figure 20) for the genotypes (TG)12T5 / 
(TG)12T5 and (TG)10T9 / (TG)10T9 their different effect on 
the splicing of exon 9 are evidenced: (TG)12T5 / (TG)12T5 
shows two bands, the higher one, wild-type and little visible, 
and the lower one, that resulted from a very marked exclusion 
of exon 9; on the contrary, (TG)10T9 / (TG)10T9 shows a 
single band (the wild-type one) evidencing that this tract does 
not cause a significant anomalous splicing of the CFTR. 
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The semi-quantitative densitometric analysis revealed the 
average percentages of splicing, summarized in Table 3. The 
(TG)mTn genotype is shown in the first column; in the second 
and third columns there are the averages of the densitometric 
analysis of the results obtained for both the higher band (Exon 
9+) and the lower band (Exon 9-). As shown, the genotypes 
including variant tracts (TG)11T5, (TG)13T5, (TG)12T7 and 
Figure 20. Examples of 1.5% agarose gel electrophoresis of RT-PCRs 
of different genotypes (TG)mTn of interest. 
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(TG)12T5 show lower percentages of higher band (wild-type 
band with exon 9) and higher percentages of lower band 
(mutated band without exon 9); it does not happen for any of 
the other tracts. Even, the genotypes (TG)10T9 / (TG)10T9 and 
(TG)10T7 / (TG)10T9 show a percentage of abnormal splicing, 
respectively, equal or near to 0. This confirms and extends 
what is already known in literature and well correlates with our 
(TG)mTn frequency study. Those tracts, able to significantly 
reduce the amount of wild-type mRNA and consequently of 
functional protein, are those more frequent in the target 
populations. Moreover, it should be noted that the variant tract 
(TG)12T7, which is usually considered not to cause a high 
percentage of abnormal splicing, in one of our cases produces, 
in homozygosis, an 81.4% of mutated transcript. 
The results obtained with densitometric analysis were verified 
through the use of specific TaqMan probes in Real-time PCR. 
For this quantitative study, it was initially necessary to 
construct the reference plasmidic curve, using mixes with 
known concentrations of plasmid containing exon 9 (PL CF 
9+) and plasmid not containing exon 9 (PL CF 9-). The curve 
was based on the logarithmic relationships between plasmids: 
in particular we obtained two different trends, with two 
different formulas, and we calculate the percentage of splicing 
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between 1% and 10% with the leftmost curve (in blue) and the 
percentage of splicing between 10% and 90% with the 
rightmost curve (in orange) (Figure 21). 
The Real-time PCR results are illustrated in Table 3. The 
(TG)mTn genotype is shown in the first column; in the fourth 
and fifth columns there are the averages of the Real-time PCR 
PL CF 9- PL CF 9+
1% 99%
2% 98%
4% 96%
6% 94%
8% 92%
10% 90%
PL CF 9- PL CF 9+
10% 90%
20% 80%
30% 70%
40% 60%
50% 50%
60% 40%
70% 30%
80% 20%
90% 10%
Figure 21. Plasmidic curve of the logarithmic relationships between plasmid 
containing exon 9 and plasmid not containing exon 9. The concentrations of 
each plasmid are indicated in the tables on the bottom, both for the leftmost 
curve (in blue) and for the rightmost curve (in orange). 
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Table 3. Summary of the average percentages of Exon 9+ and Exon 9- in the 
functional analysis of variant tracts (TG)mTn. The (TG)mTn genotype is 
shown in the first column; in the second and third columns there are the 
averages of the densitometric analysis; in the fourth and fifth columns there are 
the averages of the Real-time PCR analysis. In violet the genotypes for which 
both densitometry and Real-time PCR analysis were performed, in pink those 
for which only the densitometric analysis was carried out, in light blue those 
for which only the Real-time PCR analysis was carried out. 
Exon 9+ Exon 9- Exon 9+ Exon 9-
(TG)10T9 / (TG)10T9 100,0 0,0 90,2 9,8
(TG)10T7 / (TG)11T7 87,1 12,9 87,2 12,8
(TG)10T7 / (TG)10T9 98,4 1,6 86,8 13,2
(TG)10T9 / (TG)11T7 94,9 5,1 77,0 23,0
(TG)10T7 / (TG)10T7 82,7 17,3 76,2 23,8
(TG)10T7 / (TG)12T7 87,5 12,5 73,0 27,0
(TG)11T7 / (TG)11T7 82,0 18,0 61,6 38,4
(TG)13T6 / (TG)12T7 38,7 61,3
(TG)12T5 / (TG)12T7 36,0 64,0
(TG)11T5 / (TG)11T7 35,4 64,7
(TG)10T9 / insT 37,7 62,3 34,4 65,6
(TG)13T5 / (TG)11T7 20,1 79,9 29,8 70,2
(TG)11T5 / (TG)11T5 33,6 66,4 29,2 70,8
(TG)12T7 / (TG)12T7 18,6 81,4
(TG)12T5 / (TG)12T5 12,7 87,3 7,2 92,8
DENSITOMETRIC ANALYSIS 
AVERAGES
REAL-TIME PCR ANALYSIS 
AVERAGES(TG)mTn
analysis of the results obtained for both cDNA with exon 9 
(Exon 9+) and cDNA without exon 9 (Exon 9-). Also in this 
case, the genotypes including variant tracts (TG)11T5, 
(TG)13T5 and (TG)12T5 show low percentages of wild-type 
mRNA and high percentages of mutated mRNA. These results 
confirm, also by Real-time PCR, that these tracts are able to 
greatly influence the quantity of CFTR wild-type mRNA.  
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In Table 4 the individual percentages of Exon 9+ and Exon 9- 
of the subjects included in Real-time PCR functional studies 
were reported, for a total of 31 individuals. They were divided 
according to their (TG)mTn genotype, with increasing average 
splicing values, as in Table 3. In the first column the 
numeration is indicated; in the second the CF population to 
which the subject belongs; in the third the basic genotype; in 
the fourth the (TG)mTn genotype; in the fifth the starting 
material from which the RNA was extracted; in the sixth and 
seventh the individual percentages of Exon 9+ and Exon 9-; in 
the octave and in the ninth the average percentages of Exon 9+ 
and Exon 9- (as in Table 3). Some subjects are parents or 
partners of CF patients, on which we had already carried out 
other studies, and were included in this study because their 
RNA was available and their (TG)mTn was of interest. For 
three individuals we do not have Real-time PCR data and only 
the percentages obtained from the densitometric analysis are 
presented (they are indicated with a red label on the right of the 
table). 
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Table 4. List of the subjects included in Real-time PCR functional studies. In 
the first column there is the numeration; in the other columns it is indicated 
the CF population, the basic genotype, the (TG)mTn, the RNA collection, the 
individual and the average percentages. The values obtained only with 
densitometric analysis are indicated with *DENS (in red) on the right of the 
table. 
Exon 9+ Exon 9- Exon 9+ Exon 9-
1 CF
F508del /               
1585-9412A>G
(TG)10T9 / 
(TG)10T9
Brushing 94.0 6.0 90.2 ± 3.6 9.8 ± 3.6
2 CF F508del / F508del
(TG)10T9 / 
(TG)10T9
CRC cells 89.9 10.1
3 CF
[F508del;I1027T] / 
F508del
(TG)10T9 / 
(TG)10T9
CRC cells 86.8 13.2
4 GEN [G576A;R668C] / N
(TG)10T7 / 
(TG)11T7
CRC cells 87.2 12.8 87.2 ± 0.0 12.8 ± 0.0
5 CF
W1282X / 
[R117L;L997F]
(TG)10T9 / 
(TG)10T7
Brushing 90.9 9.1 86.8 ± 9.1 13.2 ± 9.1
6 CF F508del / 328del538
(TG)10T9 / 
(TG)10T7
Brushing 91.9 8.1
7 CF
F508del /                
del Ex14b-17b
(TG)10T9 / 
(TG)10T7
Brushing 91.2 8.8
8 CF F508del / UN
(TG)10T9 / 
(TG)10T7
Brushing 73.2 26.8
9 CF F508del / L558S
(TG)10T9 / 
(TG)11T7
CRC cells 77.0 23.0 77.0 ± 0.0 23.0 ± 0.0
10 GEN G576A / G576A
(TG)10T7 / 
(TG)10T7
Brushing 84.0 16.0 76.2 ± 11.0 23.8 ± 11.0
11 CF FATHER dupl Ex19 / N
(TG)10T7 / 
(TG)10T7
Brushing 68.4 31.6
12 GEN N / N
(TG)10T7 / 
(TG)10T7
Brushing 75.3 24.7 75.3 ± 0.0 24.7 ± 0.0 *DENS
13 CF
[G576A;R668C] / 
S1235R
(TG)10T7 / 
(TG)12T7
Brushing 73.0 27.0 73.0  ± 0.0 27.0 ± 0.0
14 CF R553X / del Ex2
(TG)11T7 / 
(TG)11T7
Brushing 58.8 41.2 61.6 ± 5.9 38.4 ± 5.9
15 CF UN / UN
(TG)11T7 / 
(TG)11T7
Brushing 70.1 29.9
16 CF MOTHER R553X / N
(TG)11T7 / 
(TG)11T7
Brushing 58.4 41.6
17 GEN G85E / N
(TG)11T7 / 
(TG)11T7
CRC cells 55.7 44.3
18 GEN G85E / N
(TG)11T7 / 
(TG)11T7
Brushing 65.2 34.8
19 GEN N / N
(TG)13T6 / 
(TG)12T7
Brushing 38.7 61.3 38.7 ± 0.0 61.3 ± 0.0 *DENS
20
CFTR-RD 
MOTHER
12-5 / N
(TG)12T5 / 
(TG)12T7
Brushing 36.0 64.0 36.0 ± 0.0 64.0 ± 0.0
21
CFTR-RD 
FATHER
L1065P / N
(TG)11T5 / 
(TG)11T7
Brushing 35.4 64.7 35.4 ± 0.0 64.7 ± 0.0
INDIVIDUAL 
PERCENTAGES
AVERAGE PERCENTAGES ± 
DEV. STANDARDNUMERATION
CF 
POPULATION
GENOTYPE (TG)mTn
RNA 
COLLECTION
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After evaluating the average percentages of wild-type mRNA 
with exon 9 and mutated mRNA without exon 9 in the 
genotypes (TG)mTn of interest, we compared the results 
obtained in the previous densitometric analysis and those 
obtained in Real-time PCR, as shown in Figure 22 and in 
Figure 23. The trend of the two curves, for the (TG)mTn tracts 
studied, shows that there is a good correlation between the two 
techniques and that they can be used together to study the 
splicing of CFTR exon 9, although with a few exceptions. 
Table 4 follows from the previous page. 
Exon 9+ Exon 9- Exon 9+ Exon 9-
22 CF F508del / ins317
(TG)10T9 / 
insT
CRC cells 34.8 65.2 34.4 ± 2.7 65.6 ± 2.7
23 CF F508del / ins358
(TG)10T9 / 
insT
CRC cells 32,0 68,0
24 CF F508del / ins317
(TG)10T9 / 
insT
Brushing 38.1 61.9
25 CF F508del / ins358
(TG)10T9 / 
insT
Brushing 32.8 67.2
26 GEN 13-5 / N
(TG)13T5 / 
(TG)11T7
Brushing 33.9 66.1 29.8 ± 5.8 70.2 ± 5.8
27 CF MOTHER
907delCins29 /  
13-5
(TG)13T5 / 
(TG)11T7
Brushing 25.7 74.3
28 GEN N / N
(TG)11T5 / 
(TG)11T5
Brushing 29.2 70.8 29.2 ± 0.0 70.8 ± 0.0
29 CF FATHER N / UN 
(TG)12T7 / 
(TG)12T7
Brushing 18.6 81.4 18.6 ± 0.0 81.4 ± 0.0 *D ENS
30 CF
[359insT;12-5] / 
12-5
(TG)12T5 / 
(TG)12T5
Brushing 14.4 85.6 7.2 ± 10.2 92.8 ± 10.2
31 ISHV
(TG)12T5 / 
(TG)12T5
(TG)12T5 / 
(TG)12T5
Brushing 0.0 100.0
INDIVIDUAL 
PERCENTAGES
AVERAGE PERCENTAGES ± 
DEV. STANDARDNUMERATION CF POPULATION GENOTYPE (TG)mTn
RNA 
COLLECTION
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Figure 22. Comparison between densitometric analysis and Real-time PCR 
analysis in the study of percentage of wild-type CFTR mRNA (Exon 9+). 
Figure 23. Comparison between densitometric analysis and Real-time PCR 
analysis in the study of percentage of mutated CFTR mRNA (Exon 9-). 
118 
These results allowed us to summarize the functional influence 
of all the (TG)mTn genotypes included in this study on CFTR 
splicing, estimating the final percentages of wild-type (Exon 
9+) and mutated (Exon 9-) mRNA, as shown in Figure 24 and 
in Figure 25, respectively. In general, we can assert that: 
genotypes with (TG)10T9, (TG)10T7, (TG)11T7 show high 
percentage of Exon 9+ and low percentage of Exon 9-; 
genotypes with (TG)11T5, (TG)12T5, (TG)13T5 show low 
percentage of Exon 9+ and high percentage of Exon 9-; 
genotypes with (TG)12T7 show a variable effect, spanning 
from a mild reduction of Exon 9+ to a great decrease of the 
percentage of Exon 9+, as for example for (TG)12T7 in 
homozygosis. 
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Figure 25. Percentage of mutated mRNA (Exon 9-) in all the variant tracts 
(TG)mTn included in this study. 
 
 
 
 
 
 
 
 
Figure 24. Percentage of wild-type mRNA (Exon 9+) in all the variant tracts 
(TG)mTn included in this study. 
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After completing the analysis on (TG)mTn genotypes, we 
calculated the contribution of each single (TG)mTn allele on 
the final percentage of Exon 9+ and Exon 9-, according to our 
experiments. First of all, the average percentages of Exon 9+ 
and Exon 9- in homozygotes (TG)mTn genotypes, such as 
(TG)10T9 / (TG)10T9, (TG)10T7 / (TG)10T7, (TG)11T7 / 
(TG)11T7, (TG)11T5 / (TG)11T5 and (TG)12T5 / (TG)12T5, 
were evidenced. Assuming that the contribution of each single 
allele was 50%, the values of homozygotes were divided by 
two, to obtain the percentage of the contribution of (TG)10T9, 
(TG)10T7, (TG)11T7, (TG)11T5 and (TG)12T5 single alleles 
(Table 5A). Then the contribute of the other (TG)mTn alleles, 
such as (TG)12T7, insT and (TG)13T5, were derived through 
an indirect calculation based on the previous ones, subtracting 
to the total average percentages of Exon 9+ and Exon 9- those 
obtained from homozygotes (Table 5B). We decided to 
exclude from this analysis the (TG)12T7 / (TG)12T7, for its 
singular and unexpected percentages of Exon 9+ and Exon 9- 
(that could be evaluated only by densitometric analysis), and 
the (TG)13T6, because it is a rare and little known variant tract 
and its calculation depends only on (TG)12T7. In Table 5C 
there is a summary of the average percentages of Exon 9+ and 
Exon 9- for each allele. We notice that insT and (TG)13T5 
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produce only anomalous splicing and, therefore, not functional 
CFTR transcript (Exon 9-). (TG)12T7 was calculated as an 
average of the values obtained from (TG)10T7 / (TG)12T7 and 
(TG)12T5 / (TG)12T7 (having subtracted the contribute of the 
first allele). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)10T9 (TG)10T9 (TG)10T9 / (TG)10T9
Exon 9+ 45,1 45,1 90,2
Exon 9- 4,9 4,9 9,8
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)10T7 (TG)10T7 (TG)10T7 / (TG)10T7
Exon 9+ 38,1 38,1 76,2
Exon 9- 11,9 11,9 23,8
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)11T7 (TG)11T7 (TG)11T7 / (TG)11T7
Exon 9+ 30,8 30,8 61,6
Exon 9- 19,2 19,2 38,4
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)11T5 (TG)11T5 (TG)11T5 / (TG)11T5
Exon 9+ 14,6 14,6 29,2
Exon 9- 35,4 35,4 70,8
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)12T5 (TG)12T5 (TG)12T5 / (TG)12T5
Exon 9+ 3,6 3,6 7,2
Exon 9- 46,4 46,4 92,8
TOTAL 50,0 50,0 100,0
Table 5A. Average percentages of Exon 9+ and Exon 9- for the 
alleles (TG)10T9, (TG)10T7, (TG)11T7, (TG)11T5 and (TG)12T5 
(direct calculation of their contribution on CFTR functionality). 
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ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)10T7 (TG)12T7 (TG)10T7 / (TG)12T7
Exon 9+ 38,1 34,9 73,0
Exon 9- 11,9 15,1 27,0
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)12T5 (TG)12T7 (TG)12T5 / (TG)12T7
Exon 9+ 3,6 32,4 36,0
Exon 9- 46,4 17,6 64,0
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)10T9 insT (TG)10T9 / insT
Exon 9+ 45,1 -10,7 34,4
Exon 9- 4,9 60,7 65,6
TOTAL 50,0 50,0 100,0
ALLELE 1 ALLELE 2 (TG)mTn GENOTYPE
(TG)13T5 (TG)11T7 (TG)13T5 / (TG)11T7
Exon 9+ -1,0 30,8 29,8
Exon 9- 51,0 19,2 70,2
TOTAL 50,0 50,0 100,0
Table 5B. Average percentages of Exon 9+ and Exon 9- for the 
alleles (TG)12T7, insT and (TG)13T5 (indirect calculation of their 
contribution on CFTR functionality, based on A). 
Exon 9+ Exon 9-
(TG)10T9 45,1 4,9
(TG)10T7 38,1 11,9
(TG)11T7 30,8 19,2
(TG)11T5 14,6 35,4
(TG)12T5 3,6 46,4
(TG)12T7 33,7 16,4
insT 0,0 50,0
(TG)13T5 0,0 50,0
AVERAGE PERCENTAGES
(TG)mTn ALLELE
Table 5C. Summary of the average percentages of 
Exon 9+ and Exon 9- for each allele. 
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In this work on CFTR (TG)mTn we evidenced three particular 
variant tracts, that were less considered or still not 
characterized in literature, for their complex functional activity 
on CFTR splicing: 
i. (TG)12T7 / (TG)12T7: this (TG)mTn genotype was 
found once in our case series and it was studied only 
with densitometric analysis. Our studies underlined that 
this sample showed a high percentage of abnormal 
splicing of exon CFTR 9 (81.4%), never found in 
literature in patients with this (TG)mTn genotype. We 
couldn’t examine it with Real-time PCR because the 
RNA analyzed was no longer available: in fact, this 
subject was inserted into our case series as a father of a 
CF patient, to study the mutations of the affected child 
(F508del/unknown). All the investigations were carried 
out following the standard protocols (using the first, the 
second and the third level of CFTR genetic analysis 
showed in Table 1, but also more specific and in-depth 
techniques), both on the father and on the son, but no 
other mutations were found. For these reasons we 
assume that the father may be a healthy carrier, with a 
sufficient percentage of functional protein. On the 
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contrary, his son, presenting a severe mutation on an 
allele and this particular (TG)12T7 on the other, shows 
the classical form of the pathology, because the 
reduction of functional protein is considerable. From 
the molecular point of view, we could speculate that 
this particular case may depend from the functionality 
of splicing machinery that, due to its peculiarity in this 
(TG)12T7 homozygous sample, can induce in a quote 
of anomalous splicing greater than usually. Obviously, 
additional studies are mandatory. Now we need to study 
this interesting sample with Real-time PCR and confirm 
this data, to find other (TG)12T7 / (TG)12T7 patients to 
study their percentage of splicing and to evaluate other 
causes that can contribute to this clinical picture. The 
(TG)12T7 was analyzed also with other variant tracts 
(TG)mTn in Real-time PCR: for example it shows a 
percentage of 27% of splicing when on the other allele 
there is a (TG)10T7 and a percentage of 64% of 
splicing when it is coupled with a (TG)12T5. These 
data support the hypothesis that the (TG)12T7 tract 
influences the splicing of CFTR exon 9 in a very 
variable manner. 
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ii. (TG)13T6 / (TG)12T7: also this (TG)mTn genotype 
was found just in a subject of our case series and it was 
studied only with densitometric analysis. It is a singular 
(TG)mTn because an allele presents a repetition of 13 
TG followed by a repetition of 6 T: there are no case in 
literature in which this combination appears. 
Considering that the (TG)12T7 has a very variable 
influence on exon 9 splicing, we could not calculate the 
exact reduction that the single (TG)13T6 may cause on 
the final CFTR functional mRNA. Our purpose in the 
future is to study this sample also in Real-time PCR, to 
have a more accurate feedback regarding this genotype, 
and, if we have the possibility, to study other (TG)mTn 
genotype containing the (TG)13T6 and/or to perform in 
vitro studies by expression minigenes. 
iii. (TG)10T9 / insT: two CF subjects presented this novel 
(TG)mTn genotype. We found that these patients had a 
classical (TG)10T9 on the first allele and a disrupted 
(TG)mTn on the second. It was not properly a variant 
tract (TG)mTn: in fact, we evidenced an insertion, 
coming from the intron 9 and containing a series of 
repetitions of T, introduced into the (TG)mTn (intron 
8), after the duplication of a portion of DNA. In 
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particular a patient showed an insertion of 317 bp 
(ins317), while the other an insertion of 358 bp 
(ins358): the only difference is related to the different 
number of T and this allows to speculate on a molecular 
mechanism of divergence from a common ancestral 
allele. This molecular lesions appear to alter the normal 
splicing process of CFTR. In particular, we studied this 
samples both by densitometric analysis and Real-time 
PCR and obtained percentages of anomalous transcript 
over 50%. If we consider the very limited contribution 
of (TG)10T9 allele to exon 9 anomalous splicing, as 
evidenced in literature and in our experiments, we can 
conclude that these insertions completely suppress the 
physiological splicing. Consequently, it appears to 
cause a reduction of functional protein, if matched with 
a severe mutation of CFTR on the other allele, that 
results in a classical CF form. This allows to highlight it 
as a novel CF-causing mutation of CFTR.  
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3.3 Analysis of CFTR 3’-UTR 
 
This part of the study focused on the analysis of CFTR 3’-
UTR; in particular, we searched for the sequence variations 
that may influence the action of miRNAs. Initially, a 
bibliographic, bioinformatic and database research was carried 
out with the aim of highlighting the so far known miRNAs able 
to bind the 3'-UTR of CFTR. The results of this collection is 
summarized in Table 6. The first column shows the list of 
miRNAs verified with in silico analysis (prediction analysis 
through sites such as TargetScan, MicroRNA.org, PITA, 
miRDB, Microcosm, miRBase, miRanda, PicTar, EIMMo); the 
second and third columns show for which miRNAs the binding 
in vitro has been verified, either using a luciferase assay 
(qualitative binding, second column) either verifying if their 
presence alters in some way the levels of wild-type mRNA 
produced (quantitative binding, third column); the fourth 
column shows the only two miRNAs for which the functional 
effect has been currently verified also in vivo after nasal 
epithelial brushing from patients; the last column shows the 
miRNAs with known specific binding site on the 3'-UTR, as a 
result of mutagenesis assays. 
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Table 6. Summary of the known CFTR miRNAs. In the first column 
there is the list of all the miRNAs predicted with in silico analysis; in 
the other columns it is indicated if they were verified in vitro, in vivo 
and if their binding site on CFTR 3’-UTR is known. 
Verified in vivo Binding 
miRNAs Qualitative Quantitative (after nasal site known
(In silico binding binding epithelial (Mutagenesis
analysis) (Luciferase (Regulation of brushing  analysis)
assay) CFTR mRNA) of patients)
mir-145 √ √ 427-434
mir-377 √ √
mir-384 √ √ 1113-1125 (ARE-5698)
mir-494 √ √ 1140-1146
mir-1827 √ √
mir-939 √ √
mir-331-3p √ √
mir-607 √ √
mir-600 √ √ 1498-1516 (ARE-6074)
mir-376a/b √ √
mir-1290 √ √
mir-1246 √ √
mir-101 √ √ 1501-1530
mir-144 √ √ 1501-1530
mir-199-3p √
mir-345 √
mir-380 √
mir-509-3p √ √ √ 1042-1066 (c.*1043A>C)
mir-645 √
mir-223 √ √ 1473-1481
mir-31
mir-362-5p
mir-433 √ √ √ 1042-1066 (c.*1043A>C)
mir-505 √ √
mir-943 √ √
mir-942 √
mir-665 √
mir-383 √
mir-451
mir-150
mir-221 √ √
mir-126
mir-9
mir-93
mir-224 √ √
tot. 35 tot. 28 tot. 20 tot. 2 tot. 9
Verified in vitro
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Once we highlighted the CFTR 3’-UTR zone potential target of 
known miRNAs, we planned its sequencing. To this purpose, 
we divided this zone into five portions (Figure 7). The analysis 
was carried out on subjects belonging to three specific 
categories, for a total of 108 patients, as they were the best 
candidates for these transcriptional regulation studies: patients 
presenting the same mutated genotype (two mutations found), 
but different phenotype (belonging to different CF 
populations); F508del homozygous patients, all CF-PI but with 
very different levels of the sweat tests; patients to whom only 
one of the two mutations causing the disease was found (Table 
7). The variations found on 3’-UTR are the following: 
a) *81C/T (4575+81C/T) in heterozygosis; 
b) *567C/T (4575+567C/T) in heterozygosis; 
c) *1251C/T (4575+1251C/T) both in heterozygosis and in 
homozygosis.  
All the variations resulted already known: the *1251C/T has 
already been characterized, with a clinical significance of 
“likely benign” variation; the *81C/T and the *567C/T, 
instead, have not yet been characterized. The variations found 
do not fall within the miRNA binding zones shown in the last 
column of Table 6, so their meaning at the functional level is 
still uncertain. 
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Table 7. List of the patients selected for the study on CFTR 3’-UTR. In the first 
column the genotype considered is indicated for the three categories of patients; 
in the second column the number of patients with the genotype of interest is 
evidenced; in the third column there are the CF populations to which each  
patient belongs; in the last column the 3’-UTR variations found for that specific 
patient are indicated: in red the *81C/T (4575+81C/T) in heterozygosis, in blue 
the *567C/T (4575+567C/T) in heterozygosis, in black the *1251C/T 
(4575+1251C/T) in heterozygosis and in green the *1251T/T (4575+1251T/T) in 
homozygosis. For some genotypes, we had the availability of only one patient's 
DNA, but they were inserted the same because showed the variations of interest. 
G542X / (TG)12T5 1 CBAVD *1251C/T (4575+1251C/T)
G542X / (TG)12T5 2 CFTR-RD *567C/T (4575+567C/T)
G542X / (TG)12T5 3 FC-PS
N1303K / (TG)12T5 1 CBAVD
N1303K / (TG)12T5 2 CFTR-RD
N1303K / (TG)12T5 3 CFTR-RD
N1303K / (TG)12T5 4 CFTR-RD
N1303K / (TG)12T5 5 FC-PS
F508del / L997F 1 CBAVD
F508del / L997F 2 CFTR-RD
F508del / L997F 3 CFTR-RD
F508del / L997F 4 FC-PS
F508del / (TG)12T5 1 CBAVD
F508del / (TG)12T5 2 CBAVD
F508del / (TG)12T5 3 CBAVD
F508del / (TG)12T5 4 CBAVD
F508del / (TG)12T5 5 CBAVD *1251C/T (4575+1251C/T)
F508del / (TG)12T5 6 CBAVD
F508del / (TG)12T5 7 CFTR-RD
F508del / (TG)12T5 8 CFTR-RD
F508del / (TG)12T5 9 CFTR-RD
F508del / (TG)12T5 10 FC-PS
F508del / (TG)12T5 11 FC-PS
Genotype Numeration CF population 3'UTR variations found
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Table 7 follows from the previous page. 
F508del / G85E 1 FC-PI
F508del / G85E 2 FC-PI
F508del / G85E 3 FC-PI
F508del / G85E 4 FC-PI
F508del / G85E 5 FC-PI
F508del / G85E 6 FC-PI
F508del / G85E 7 FC-PS
F508del / G85E 8 FC-PI
F508del / G85E 9 FC-PI
F508del / G85E 10 FC-PI
F508del / 2183AA>G 1 FC-PI
F508del / 2183AA>G 2 FC-PI
F508del / 2183AA>G 3 FC-PS *1251C/T (4575+1251C/T)
F508del / 2183AA>G 4 FC-PI
G85E / G85E 1 FC-PS
G85E / G85E 2 FC-PI
G85E / G85E 3 FC-PI
F508del / I1234V 1 FC-PI
F508del / I1234V 2 FC-PS
N1303K / G85E 1 FC-PI
N1303K / G85E 2 FC-PS
W1282X / 2789+5 G>A 1 FC-PI *1251T/T (4575+1251T/T)
W1282X / Q1291R 1 FC-PI *1251T/T (4575+1251T/T)
W1282X / Q1291R 2 FC-PS *1251T/T (4575+1251T/T)
W1282X / Q1291R 3 FC-PS *1251T/T (4575+1251T/T)
N1303K / 2789+5 G>A 1 FC-PS *1251C/T (4575+1251C/T)
N1303K / 2789+5 G>A 2 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 1 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 2 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 3 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 4 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 5 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 6 FC-PI *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 7 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 8 FC-PS *1251C/T (4575+1251C/T)
F508del / 2789+5 G>A 9 FC-PS *1251C/T (4575+1251C/T)
1717-1 G>A / (TG)12T5 1 CFTR-RD *1251C/T (4575+1251C/T)
1717-1 G>A / (TG)12T5 2 FC-PS *1251C/T (4575+1251C/T)
1717-1 G>A / (TG)12T5 3 FC-PS *1251T/T (4575+1251T/T)
1717-1 G>A / (TG)12T5 4 FC-PS *1251C/T (4575+1251C/T)
F508del / [(TG)11T5; V562I; A1006E] 1 FC-PS *1251C/T (4575+1251C/T)
F508del / [(TG)11T5; V562I; A1006E] 2 FC-PS *1251T/T (4575+1251T/T)
F508del / [(TG)11T5; V562I; A1006E] 3 FC-PS *1251C/T (4575+1251C/T)
Genotype Numeration CF population 3'UTR variations found
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Table 7 follows from the previous page. 
F508del / D1152H 1 CFTR-RD *1251C/T (4575+1251C/T)
F508del / D1152H 2 FC-PS *1251C/T (4575+1251C/T)
F508del / D1152H 3 FC-PS *1251C/T (4575+1251C/T)
F508del / D1152H 4 FC-PS *1251C/T (4575+1251C/T)
F508del / T338I 1 CFTR-RD
F508del / T338I 2 FC-PS
F508del / (TG)13T5 1 CFTR-RD *81C/T (4575+81C/T)
F508del / F508del 1 FC-PI
F508del / F508del 2 FC-PI
F508del / F508del 3 FC-PI
F508del / F508del 4 FC-PI
F508del / F508del 5 FC-PI
F508del / F508del 6 FC-PI
F508del / F508del 7 FC-PI
F508del / F508del 8 FC-PI
F508del / F508del 9 FC-PI
F508del / F508del 10 FC-PI
F508del / F508del 11 FC-PI
F508del / F508del 12 FC-PI
F508del / F508del 13 FC-PI
F508del / F508del 14 FC-PI
F508del / F508del 15 FC-PI
F508del / F508del 16 FC-PI
F508del / F508del 17 FC-PI
F508del / F508del 18 FC-PI
F508del / F508del 19 FC-PI
S912L / un 1 CBAVD
[M348K;S912X] / un 2 CBAVD *1251C/T (4575+1251C/T)
L997F / 711+5G>A (no segregation) 3 CBAVD *1251C/T (4575+1251C/T)
G1069R / un 4 CBAVD
(TG)12T5 / un 5 CBAVD *1251C/T (4575+1251C/T)
[(TG)11T5;V562I;A1006E] / un 6 CBAVD *1251T/T (4575+1251T/T)
S42F / un 7 CBAVD *1251C/T (4575+1251C/T)
W1282X / un 8 CFTR-RD *1251T/T (4575+1251T/T)
F508del / un 9 FC-PI
G85E / un 10 FC-PI
F508del / un 11 FC-PS
F508del / un 12 FC-PS
G85E / un 13 FC-PS
[1249-8A>G;G576A;R668C] / un 14 FC-PS *1251C/T (4575+1251C/T)
(TG)12T5 / un 15 FC-PS *1251C/T (4575+1251C/T)
S549R(A>C) / un 16 FC-PS
Genotype Numeration CF population 3'UTR variations found
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4. DISCUSSION
The CF phenotype is notably heterogeneous, even among 
subjects with identical CFTR mutations, due to a complex 
combination of intragenic and extragenic causes that contribute 
to the definition of the severity of the disease. We know that 
the extragenic variability is due to the existence of modifying 
genes that modulate the original effect of CFTR mutations, but 
most important may be the intragenic variability, due to the 
large number of mutations of the CFTR gene and to the even 
greater number of their possible combinations. Some examples 
can be the possible presence of complex alleles, that carry two 
or more variants in cis on the same allele, that constitute 
inheritable intragenic haplotypes; the transcriptional regulation 
in particular zones of the gene, like 5’-UTR and 3’-UTR; the 
so-called “long range interaction” of CFTR with neighboring 
genes. 
For a better understanding of the aspects concerning the 
transcriptional regulation of CFTR and, consequently, the 
production of the messenger RNA and functional protein, is 
important to study the intra-CFTR variability and to compare 
patients with apparently identical genotypes. This can help not 
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only in terms of diagnosis of the disease and of definition of 
clinical categories of CF and related pathologies, but also to 
establish new approaches of screening and of personalized 
therapy applied on the individual patient. Therefore, there is a 
strong need to deepen various aspects of the pathology related 
to the so-called "genotype-phenotype" relationship. It results 
still little known and understood in CF: in fact, in many cases, 
there is no clear correlation between the sequence variations 
found in the CFTR gene and the patients’ clinical 
manifestations. This happens in both the "classical" forms of 
CF and in those "non-classical", whose interpretation is more 
difficult. 
The purpose of this study was, therefore, to give evidence to 
the intragenic modulators of CFTR and to investigate what 
may be their actual role in the context of the disease focusing 
the attention on three actors involved in the transcriptional 
regulation of the gene: intragenic haplotypes, variant tracts 
(TG)mTn and 3'-UTR variant. We studied them both from a 
structural and a functional point of view in different CF 
populations, to assess their contribution both quantitatively and 
qualitatively in defining the final clinical CF phenotype. 
As already mentioned, a specific study has been carried out 
regarding intragenic haplotypes. The onset of a variant occurs 
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following a single mutational event that manifests itself with a 
very low frequency (in the order of 10-8 for each generation) 
compared to the number of generations that separate two 
individuals from their nearest common ancestor. For this 
reason, every new variant is initially associated with the other 
variants that are in the proximity of the chromosomal locus in 
which the mutation occurred. The specific set of variants that 
are on the same chromosome or in the same sub-chromosomal 
region is called “haplotype”. The analysis conducted, extended 
to CF and CF-like populations, selected two specific intragenic 
haplotypes. We called the first one “target”, because it was 
mainly represented in the target populations compared to 
controls: in fact, it appears mainly in ISHV, CBAVD and 
CFTR-RD alleles (13%, 20% and 36% respectively), while it is 
poorly evident in the population of normospermic subjects (6% 
of alleles) and in the general one (3% of alleles). This trend is 
even more explicit in the populations with classical CF (in 33% 
and 63% of CF-PS and CF-PI alleles, respectively). These 
evidences emphasize that the prevalence of this selected 
haplotype increases with the increasing severity of the clinical 
phenotype of the population considered. It can be seen as a 
“pathogenic” haplotype, for its correlation with affected 
populations. On the other hand, the second selected haplotype, 
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called “control” for its prevalence in the control populations, 
shows a completely opposite trend, with a prevalence in 
normospermic subjects (56% of alleles) and in general 
population (53% of alleles) compared to all the target 
populations. So, it can be seen as a "protective" haplotype, for 
its correlation with not affected populations. Searching for a 
functional effect of these haplotypes, we functionally analyzed 
the single variations included. We demonstrated that there are 
no differences in the splicing process of CFTR mRNA related 
to the individual presence of a variation which belongs or not 
to the target haplotype. In fact, all the experiments on CFTR 
mRNA evidenced that there are no anomalous forms of 
splicing caused by the presence of a single variation of the 
target haplotype. Another functional hypothesis may be that 
they have to be present together to influence wild-type 
messenger levels. Definitely, it is possible that the 
simultaneous presence in cis of the variations that compose 
haplotypes can influence the processing of the primary 
transcript of CFTR, conditioning its functionality. This aspect 
is now under investigation. An alternative hypothesis is that 
haplotypes are markers of mutated alleles. In this regard, 
particularly interesting is that the target haplotype is present on 
the majority of CF-PI alleles; in fact, since the CF-PI patients 
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have a high frequency of classical CFTR mutations, finding the 
target haplotype increases the probability that on that allele a 
classical mutation will be present at the same time. 
Consequently, haplotype analysis could be a quick approach to 
the detection of mutated alleles, also in broad spectrum 
screening programs. 
The splicing process is very complex and often in many 
diseases, such as for example the CF, the molecular defect is 
due to alterations of this mechanism. The knowledge of the 
complexity of the splicing process revealed the existence of 
important elements of regulation. Variations of these elements, 
which are found both in coding and non-coding regions of the 
genes, can occur with deleterious effects on the pre-mRNA 
splicing. Even the so-called “silent” variations (which do not 
change the amino acid), as well as variations of the intronic 
sequences, can therefore be responsible for pathologies. In this 
contest, we considered very important to include in this study 
the analysis of the variant tract (TG)mTn, which is located on 
intron 8 of the CFTR gene and that regulates the splicing of 
exon 9. Based on literature data and results previously obtained 
by my research group, we decided to focus our attention on the 
variants (TG)13T5, (TG)12T7, (TG)11T5 and (TG)12T5. We 
demonstrated that they have a greater frequency in the 
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populations with infertility (ISHV and CBAVD) and 
pathologies related to CF (CFTR-RD) compared to the controls 
(NORMO and GEN). This is consistent with the fact that they 
are not populations predominantly characterized by classical 
CF mutations, but from variant tracts and sequence variations 
that result in the occurrence of mono- or oligo- symptomatic 
clinical phenotype. It should also be pointed out that in 
CBAVD, population, with a more severe clinical phenotype 
(from reproductive point of view), the (TG)12T5 is at higher 
frequency than the ISHV population that shows, from 
reproductive point of view, a milder phenotype. This variant 
tract is known in literature as being, of the three analyzed, that 
lowering at the greatest extent the quantity of functional 
mRNA, and consequently of functional CFTR protein. Instead, 
in the ISHV population, the other two variant tracts analyzed, 
which have a less severe quantitative impact, are more 
represented. These variant tracts are also uncommon in 
populations with classical CF. Other tracts, such as (TG)10T9, 
(TG)11T7 or (TG)10T7, that have a cumulative frequency 
similar in all the populations (both targets and controls), do not 
seem to be involved in splicing processes, as confirmed by 
literature and our experimental data. In fact, the results 
obtained on the RNA from patients confirm that only the 
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variant tracts (TG)13T5, (TG)12T5, (TG)12T7 and (TG)11T5 
are responsible, in different percentages, of the abnormal 
exclusion of exon 9 from the mature transcript in a “clinically-
relevant” quantity. Although the splicing observed relatively to 
the tracts (TG)13T5 and (TG)12T5 confirm the literature data, 
the results obtained for the tracts (TG)11T5 and (TG)12T7 are 
different from the expected ones. In fact, these tracts are 
usually described as responsible of low levels of aberrant 
splicing of exon 9. On the contrary, in our study, subjects with 
the (TG)11T5 / (TG)11T5 genotype show a percentage of 
splicing of 70% and in one (TG)12T7 / (TG)12T7 subject a 
splicing of the exon 9 of over 80% was evidenced, never found 
so high for this tract. This is surprising because until now such 
a high production of anomalous messenger has never been 
highlighted starting from these variant tracts, described so far 
as non-pathological. A possible explanation of the data can be 
based on the fact that, in some specific cases and genetic 
background, the variant tracts (TG)11T5 and (TG)12T7 can 
show an increased anomalous splicing. In addition, both variant 
tracts have been found in cis, on the same allele, with other 
sequence variations to constitute a complex allele. Often, also 
the sequence variations in cis can influence the maturation, 
levels of transcripts and amount of functional protein. It should 
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be considered that these variant tracts are more frequent in CF 
populations with mild clinical manifestations and CF-like 
population and that at the functional level they are able to 
partially influence the levels of protein that reach the apical 
membrane of the epithelial cells. Consequently, it seems 
appropriate to point out the (TG)mTn as an important 
modulator of the CFTR transcription and to evaluate it 
effectively in terms of genetic assessment. 
The 3’-UTR of a gene is the zone of messenger RNA that 
immediately follows the translation termination codon. The 3'-
UTR often contains regulatory regions that post-
transcriptionally influence gene expression, both binding sites 
for regulatory proteins as well as microRNAs (miRNAs). By 
binding to specific sites within the 3'-UTR, miRNAs can 
decrease gene expression of various mRNAs by either 
inhibiting translation or directly causing degradation of the 
transcript. The knowledge of this particular region in CFTR is 
still not very detailed and, for this reason, it can be useful to 
study it in patients of particular clinical interest, in which the 
genotype-phenotype correlation is not clear. The symptomatic 
manifestations of a patient do not depend only from the first 
two sequence variations found. The 3’-UTR variants may be 
additional intragenic modulator important for both diagnostic 
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and therapeutic assessment. Our study highlighted three 
variations on the 3'-UTR of some subjects, which were already 
previously known and named *81C/T, *567C/T and *1251C/T; 
while the *1251C/T is already characterized and with a non-
pathological functional significance, there is very little 
information of the other two variations in literature and they 
are not yet characterized at functional level. This correlates 
with the results we have seen in our 3'-UTR case series, that is 
that the variation *1251C/T is found in almost half of the 
subjects and is therefore very frequent, while the *81C/T and 
the *567C/T are present in only one patient each and therefore 
they are rare. Although they are not found in any of the known 
miRNAs binding sites, it can’t be ruled out that they may be 
within unexplored binding sites and may interact with CFTR 
miRNAs that are not yet characterized. Obviously, also an 
alternative explanation exist for the variability possibly 
dependent on miRNA. It may depend on different amount of 
miRNAs present and able to interact with the 3'-UTR; in fact, 
also variations in the production machinery of miRNAs, which 
can cause an increased or decreased production of them, could 
influence the percentage of CFTR messenger present in the 
cell. In this case, a miRNA could act both negatively, when its 
presence is increased and therefore it binds more mRNA, than 
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positively, when it is less produced and therefore higher 
messenger levels can be maintained. 
Our studies allow us to formulate a model that concerns the 
role of intragenic modifiers of CFTR, additional to that of 
classic mutations, in the modulation of its transcriptional 
activity. They can be able, in different ways, to influence the 
classical gene transcription scheme and to contribute to the 
determination of the quantity and quality of messenger RNA 
and, consequently, of the phenotypic characteristics of patients. 
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5. CONCLUSIONS 
 
Due to its different frequency in the analyzed CF populations, 
the intragenic haplotype studied in this work may be 
considered a possible intragenic modulator, with an effect (at 
least in some cases) possibly additional to that of principal 
CFTR mutations. A mode of functional action may be the 
modulation of CFTR mRNA expression. Although there is no 
evidence of a functional role of the individual variations of the 
haplotype, it would be interesting to study their cumulative 
effect on CFTR mRNA level. Moreover, it was found that the 
identification of this particular haplotype marks, in 63% of 
cases, a mutated allele of classical severe forms of CF: so it can 
be seen also as a marker of these mutated alleles. The use of 
this haplotype can be to the basis of broad-spectrum screening 
programs (for example for the carrier screening), with 
significant cost savings and reduction of investigation times. 
  
The analysis of the wild-type CFTR messenger allowed us to 
quantify the transcriptional modulation activity of the variant 
tracts (TG)mTn, particularly involved, in specific CF and CF-
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like populations, in the defining of the functional protein 
amount. Our results point to the variant tract (TG)mTn as an 
intragenic modulator, both for the different frequency of some 
specific tracts in the analyzed populations and for their 
demonstrated functional effect. The pathological mode of 
action seems to be the lowering of wild-type CFTR mRNA, in 
some cases additional to the presence of other CFTR 
mutations.  
 
Through the analysis of the 3'-UTR of CFTR gene, we 
improved the knowledge of poor studied CFTR portions. In 
some cases, we found variants within the 3'-UTR that may play 
a functional role. However, the 3’-UTR variants seems to be 
less frequent than the other intragenic variants. Therefore, 3'-
UTR variations would not seem to contribute extensively to the 
intragenic modulation. 
 
In CF and CF-like diseases, the intragenic variability is one of 
the components of the complex relationship between genotype 
and phenotype. The presence of intragenic modulators could 
have a higher prevalence than that previously known. In 
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particular, our study, designed on three levels of analysis, helps 
to shed light on the transcriptional regulation processes of 
CFTR. It emphasizes the importance to search for variants 
additional to classic mutations, at least in those cases where a 
discrepancy between the clinical severity of the disease and the 
genotype (limited to the first 2 mutations found on different 
alleles) is present.  
 
The full mutational and clinical characterization of CF and CF-
like patients reveals a genetic heterogeneity that implies a 
correlation between genotypic patterns and phenotype of 
macro-categories more complex than that so far known. In 
particular, the different prevalence of haplotypes and variant 
tracts in the different populations analyzed seems to contribute 
to the genotype-phenotype correlation.  
 
Because of the specificity of the sequence variations studied, 
their functional characterization is essential, with particular 
regard to a possible effect on mRNA splicing. In these cases, to 
study the functional effect of these variations and to establish 
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their possible pathogenic role, the ex vivo approach using nasal 
brushing revealed to be particularly indicated. 
The in-depth study on intragenic modulators of CFTR may 
allow to define appropriate diagnostic and therapeutic 
strategies, as well as to better clarify the relationship between 
sequence variations in DNA (genotype) and clinical 
manifestations (phenotype) in CF. 
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